

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3988290

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP
RESUBMIT DOCUMENT ID:	503924243

CONVEYING PARTY DATA

Name	Execution Date
AMYLIN PHARMACEUTICALS, LLC	08/08/2012

RECEIVING PARTY DATA

Name:	ASTRAZENECA PHARMACEUTICALS LP
Street Address:	1800 CONCORD PIKE
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19803
Name:	AMYLIN PHARMACEUTICALS, LLC
Street Address:	9360 TOWNE CENTRE DRIVE
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13852899

CORRESPONDENCE DATA**Fax Number:**

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 617 542-6000
Email: tbarnett@mintz.com
Correspondent Name: MINTZ LEVIN
Address Line 1: ONE FINANCIAL CENTER
Address Line 4: BOSTON, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	49198-501C01US
NAME OF SUBMITTER:	STEVEN C. KOERBER
SIGNATURE:	/Steven C. Koerber /

DATE SIGNED:

08/02/2016

Total Attachments: 66

source=Amylin_AZ_Assignment#page1.tif
source=Amylin_AZ_Assignment#page2.tif
source=Amylin_AZ_Assignment#page3.tif
source=Amylin_AZ_Assignment#page4.tif
source=Amylin_AZ_Assignment#page5.tif
source=Amylin_AZ_Assignment#page6.tif
source=Amylin_AZ_Assignment#page7.tif
source=Amylin_AZ_Assignment#page8.tif
source=Amylin_AZ_Assignment#page9.tif
source=Amylin_AZ_Assignment#page10.tif
source=Amylin_AZ_Assignment#page11.tif
source=Amylin_AZ_Assignment#page12.tif
source=Amylin_AZ_Assignment#page13.tif
source=Amylin_AZ_Assignment#page14.tif
source=Amylin_AZ_Assignment#page15.tif
source=Amylin_AZ_Assignment#page16.tif
source=Amylin_AZ_Assignment#page17.tif
source=Amylin_AZ_Assignment#page18.tif
source=Amylin_AZ_Assignment#page19.tif
source=Amylin_AZ_Assignment#page20.tif
source=Amylin_AZ_Assignment#page21.tif
source=Amylin_AZ_Assignment#page22.tif
source=Amylin_AZ_Assignment#page23.tif
source=Amylin_AZ_Assignment#page24.tif
source=Amylin_AZ_Assignment#page25.tif
source=Amylin_AZ_Assignment#page26.tif
source=Amylin_AZ_Assignment#page27.tif
source=Amylin_AZ_Assignment#page28.tif
source=Amylin_AZ_Assignment#page29.tif
source=Amylin_AZ_Assignment#page30.tif
source=Amylin_AZ_Assignment#page31.tif
source=Amylin_AZ_Assignment#page32.tif
source=Amylin_AZ_Assignment#page33.tif
source=Amylin_AZ_Assignment#page34.tif
source=Amylin_AZ_Assignment#page35.tif
source=Amylin_AZ_Assignment#page36.tif
source=Amylin_AZ_Assignment#page37.tif
source=Amylin_AZ_Assignment#page38.tif
source=Amylin_AZ_Assignment#page39.tif
source=Amylin_AZ_Assignment#page40.tif
source=Amylin_AZ_Assignment#page41.tif
source=Amylin_AZ_Assignment#page42.tif
source=Amylin_AZ_Assignment#page43.tif
source=Amylin_AZ_Assignment#page44.tif
source=Amylin_AZ_Assignment#page45.tif
source=Amylin_AZ_Assignment#page46.tif

source=Amylin_AZ_Assignment#page47.tif
source=Amylin_AZ_Assignment#page48.tif
source=Amylin_AZ_Assignment#page49.tif
source=Amylin_AZ_Assignment#page50.tif
source=Amylin_AZ_Assignment#page51.tif
source=Amylin_AZ_Assignment#page52.tif
source=Amylin_AZ_Assignment#page53.tif
source=Amylin_AZ_Assignment#page54.tif
source=Amylin_AZ_Assignment#page55.tif
source=Amylin_AZ_Assignment#page56.tif
source=Amylin_AZ_Assignment#page57.tif
source=Amylin_AZ_Assignment#page58.tif
source=Amylin_AZ_Assignment#page59.tif
source=Amylin_AZ_Assignment#page60.tif
source=Amylin_AZ_Assignment#page61.tif
source=Amylin_AZ_Assignment#page62.tif
source=Amylin_AZ_Assignment#page63.tif
source=Amylin_AZ_Assignment#page64.tif
source=Amylin_AZ_Assignment#page65.tif
source=Amylin_AZ_Assignment#page66.tif


AMYLIN PHARMACEUTICALS, LLC

CERTIFICATION

I, Katherine R. Kelly, the duly appointed Secretary of Amylin Pharmaceuticals, LLC, a Delaware limited liability company (the "Company"), DO HEREBY CERTIFY that, pursuant to the resolution of the Board of Directors of the Company adopted on January 28, 2013, attached hereto as Exhibit A, each of the below named persons is authorized to sign, individually, on behalf of Amylin Pharmaceuticals, LLC:

- Briana Bergen
- Elisabeth Bradley
- Laura Caponi
- Paul Golian
- Henry Hadad
- Barry Jacobsen
- Warren Volles


IN WITNESS WHEREOF, I have hereunto set my hand on this 24 day of July, 2013.


 Name: Katherine R. Kelly
 Title: Secretary

STATE OF NEW YORK)
) ss:
 COUNTY OF NEW YORK)

On this 24th day of July, 2013, before me, Janelle Clark, Notary Public, personally appeared Katherine R. Kelly, personally known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that she executed the same in her authorized capacity, and that by her signature on the instrument the person, or the entity upon behalf of which the persons acted, executed the instrument.

WITNESS my hand and official seal



 Janelle Clark
 Notary Public

JANELLE CLARK
 Notary Public, State of New York
 No. 01CL4964952
 Qualified in New York County
 Commission Expires April 16, 20 14

EXHIBIT A

RESOLVED, that effective the date hereof, and until further action by this Board of Managers, any employee of this company or of Bristol-Myers Squibb Company who is (i) a Director or above, or (ii) at a grade level of D08 or higher, be and each of them hereby is, authorized to sign, execute and deliver, in the name and on behalf of this corporation, any and all instruments including, without limitation, deeds, contracts, license agreements, leases, purchase and sales agreements, patent and trademark applications, powers of attorney and other papers relating to the business of this corporation, provided that (i) such instrument is within the scope of such individual's area of responsibility and (ii) all necessary approvals for the underlying transaction have been obtained.

IN WITNESS WHEREOF, the Assignee acknowledges and accepts this assignment this 18th day of September, at Wilmington, Delaware.

ASSIGNEE:
AstraZeneca Pharmaceuticals LP

By: *Stephen F. Mohr*
Stephen F. Mohr
US General Counsel and
Regional Legal Director, Americas
AstraZeneca Pharmaceuticals LP,

STATE OF)
) ss
COUNTY OF)

On the 18th day of September 2012, before me personally came Stephen F. Mohr, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as US General Counsel and Regional Legal Director, Americas of AstraZeneca Pharmaceuticals LP, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

Notary Public

Carol C. Denis




Exhibit A to Patent Assignment Effective August 8, 2012
Between Amylin Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals LP

Docket No.	Country	Title	App. No.	App. Date	Patent No.	Grant Date
0101PCT	PCT	Treatment of Pancreatitis with Amylin	PCT/US2003/30224PC	9/24/2003		
0101US-PRO	United States	Treatment of Pancreatitis with Amylin	60/413419	9/24/2002		
0101US-PRO2	United States	Treatment of Pancreatitis with Amylin	60/419440	10/18/2002		
0101US-UTL	United States	Treatment of Pancreatitis with Amylin	10/671304	9/24/2003	8168233	5/1/2012
0102AU	Australia	Use of Amylin Agonists to Modulate Triglycerides	2003235742	1/8/2003	2003235742	11/21/2008
0102CA	Canada	Use of Amylin Agonists to Modulate Triglycerides	2475173	1/8/2003		
0102DE	Germany	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	60324387.8-08	10/29/2008
0102EP	Europe	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	1474164	10/29/2008
0102ES	Spain	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	2316757	10/29/2008
0102FR	France	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	1474164	10/29/2008
0102GB	Great Britain	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	1474164	10/29/2008
0102IT	Italy	Use of Amylin Agonists to Modulate Triglycerides	EP 1474164	1/8/2003	33771 BE/2008	10/29/2008
0102NZ	New Zealand	Use of Amylin Agonists to Modulate Triglycerides	534557	1/8/2003	534557	2/8/2008
0102PCT	PCT	Use of Amylin Agonists to Modulate Triglycerides	PCT/US2003/00369	1/8/2003		
0102US-PRO	United States	Use of Amylin Agonists to Modulate Triglycerides	60/347128	1/8/2002		
0102US-UTL	United States	Use of Amylin Agonists to Modulate Triglycerides	10/337979	1/8/2003		
0103AU	Australia	Formulations for Amylin Agonist Peptides	2003238862	5/30/2003	2003238862	11/13/2008
0103NZ	New Zealand	Formulations for Amylin Agonist Peptides	536813	5/30/2003	536813	9/13/2007
0103PCT	PCT	Formulations for Amylin Agonist Peptides	PCT/US2003/17226	5/30/2003		
0103US-CIP1	United States	Formulations for Amylin Agonist Peptides	10/159779	5/31/2002	7312196	12/25/2007

0105AU	Australia	Amylin Family Peptides and Methods for Making and Using Them	2005320351	2/11/2005	2005320351	9/16/2010
0105BR	Brazil	Amylin Family Peptides and Methods for Making and Using Them	PI0507623-4	2/11/2005		
0105CA	Canada	Amylin Family Peptides and Methods for Making and Using Them	2556226	2/11/2005		
0105CH	Switzerland	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	1716172	6/16/2010
0105CN	China P.R.	Amylin Family Peptides and Methods for Making and Using Them	200580012043.0	2/11/2005		
0105DE	Germany	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	60021858.0-08	6/16/2010
0105EP	Europe	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	1716172	6/16/2010
0105EP-D1	Europe	Amylin Family Peptides and Methods for Making and Using Them	10006105	2/11/2005		
0105ES	Spain	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	2345113	6/16/2010
0105FR	France	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	1716172	6/16/2010
0105GB	Great Britain	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	1716172	6/16/2010
0105IL	Israel	Amylin Family Peptides and Methods for Making and Using Them	177230	2/11/2005		
0105IL-D1	Israel	Amylin Family Peptides and Methods for Making and Using Them	202795	2/11/2005		
0105IN	India	Amylin Family Peptides and Methods for Making and Using Them	4481/DELNP/06	2/11/2005		
0105IT	Italy	Amylin Family Peptides and Methods for Making and Using Them	5723040.1	2/11/2005	1716172	6/16/2010
0105JP	Japan	Amylin Family Peptides and Methods for Making and Using Them	2007-501804	2/11/2005		
0105KR	Korea South	Amylin Family Peptides and Methods for Making and Using Them	10-06-7018379	2/11/2005		
0105MX	Mexico	Amylin Family Peptides and Methods for Making and Using Them	2006/009243	2/11/2005	286390	5/9/2011
0105NZ	New Zealand	Amylin Family Peptides and Methods for Making and Using Them	549332	2/11/2005	549332	3/12/2009
0105NZ-D1	New Zealand	Amylin Family Peptides and Methods for Making and Using Them	571824	2/11/2005	571824	8/12/2010
0105RU	Russia	Amylin Family Peptides and Methods for Making and Using Them	2006132293	2/11/2005	2385878	4/10/2010
0105RU-D1	Russia	Amylin Family Peptides and Methods for Making and Using Them	2009143505	2/11/2005		
0105SG	Singapore	Amylin Family Peptides and Methods for Making and Using Them	200605364-9	2/11/2005		
0105US-DIV2	United States	Amylin Family Peptides	13/364250	2/1/2012		

0105US-PRO1	United States	Compositions and Methods for the Treatment of Obesity	60/543275	2/11/2004		
0105US-UTL2	United States	Amylin Family Peptides	10/589054	2/11/2005	8114958	2/14/2012
0105WO1	PCT	Amylin Family Peptides and Methods for Making and Using Them	PCT/US2005/004631	2/11/2005		
0105ZA	South Africa	Amylin Family Peptides and Methods for Making and Using Them	2006/07192	2/11/2005	2006/07192	2/27/2008
0106PCT	PCT	Methods for Affecting Body Composition	PCT/US2005/017227	5/17/2005		
0106US-CON1	United States	Methods for Affecting Body Composition	12/055147	3/25/2008		
0106US-PRO1	United States	Methods for Affecting Body Composition	60/550447	3/4/2004		
0106US-UTL	United States	Methods for Affecting Body Composition	10/851574	5/20/2004	7399744	7/15/2008
0108EP	Europe	Amylin Family Polypeptide-6 (afp-6) Analogs and Methods of Making and Using Them	5806753.9	10/11/2005		
0108EP-D1	Europe	Amylin Family Polypeptide-6 (afp-6) Analogs and Methods of Making and Using Them	10009542.1	10/11/2005		
0108IN	India	Amylin Family Polypeptide-6 (afp-6) Analogs and Methods of Making and Using Them	2203/DELNP/2007	10/11/2005		
0108US-PRO1	United States	AFP-6 Analogs and Uses Thereof	60/617468	10/8/2004		
0108US-UTL1	United States	Amylin Family Polypeptide-6 (afp-6) Analogs and Methods of Making and Using Them	11/664750	10/11/2005	7928060	4/19/2011
0108WO1	PCT	Amylin Family Polypeptide-6 (afp-6) Analogs and Methods of Making and Using Them	PCT/US2005/036456	10/11/2005		
0109AT1	Austria	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	E427759	4/8/2009
0109AU1	Australia	Treatment of Obesity and Related Disorders	2005305036	11/1/2005	2005305036	6/23/2011
0109AU4	Australia	Methods for Treating Obesity and Obesity Related Diseases and Disorders	2007360979	11/14/2007		
0109BE1	Belgium	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109BR1	Brazil	Methods for Treating Obesity and Obesity Related Diseases and Disorders	PI0518241-7	11/1/2005		
0109BR4	Brazil	Methods for Treating Obesity and Obesity Related Diseases and Disorders	PI0722276-9	11/14/2007		

		Disorders				
0109CA1	Canada	Treatment of Obesity and Related Diseases and Disorders	2584806	11/1/2005		
0109CA4-LL	Canada	Methods for Treating Obesity and Obesity Related Diseases and Disorders	2705708	11/14/2007		
0109CH1	Switzerland	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109CN1	China P.R.	Methods for Reducing Body Weight	200580045679.5	11/1/2005		
0109CN4	China P.R.	Methods for Treating Obesity and Obesity Related Diseases and Disorders	200780102215.2	11/14/2007		
0109CO4-LL	Colombia	Pharmaceutical Composition Comprising an Amylin, an Amylin Analog or an Amylin Agonist and a Leptin, a Leptin Derivative or a Leptin Agonist	10070926	11/14/2007		
0109DE1	Germany	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	6.02005E+11	4/8/2009
0109DK1	Denmark	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109EC4	Ecuador	Methods for Treating Obesity and Obesity Related Diseases and Disorders	SP-10-10250	11/14/2007		
0109EP1	Europe	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109EP1-D1-LL	Europe	Treatment of Obesity and Related Disorders	9003342.4	11/1/2005		
0109EP1-D2	Europe	Treatment of Obesity and Related Disorders	10178803.2	9/23/2010		
0109EP1-D3	Europe	Treatment of Obesity and Related Disorders	10178805.7	9/23/2010		
0109EP1-D4	Europe	Treatment of Obesity and Related Disorders	10178800.8	9/23/2010		
0109EP1-D5	Europe	Treatment of Obesity and Related Disorders	10178797.6	9/23/2010		
0109EP4	Europe	Methods for Treating Obesity and Obesity Related Diseases and Disorders	7868759.7	11/14/2007		
0109ES1	Spain	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109FR1	France	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009

		Disorders				
0109GB1	Great Britain	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109GE4-LL	Georgia	Methods for Treating Obesity and Obesity Related Diseases and Disorders	AP 2007 11848	11/14/2007		
0109HK1-D2	Hong Kong	Treatment of Obesity and Related Disorders	11106610.4	9/23/2010		
0109HK4	Hong Kong	Methods for Treating Obesity and Obesity Related Diseases and Disorders	11106358	11/14/2007		
0109HU1	Hungary	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109IE1	Ireland	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109IL1	Israel	Methods for Treating Obesity and Obesity Related Diseases and Disorders	182764	11/1/2005		
0109IL4	Israel	Methods for Treating Obesity and Obesity Related Diseases and Disorders	205730	11/14/2007		
0109IN4	India	Methods for Treating Obesity and Obesity Related Diseases and Disorders	3374/DELNP/2010	11/14/2007		
0109IT1	Italy	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109JP1	Japan	Methods for Treating Obesity and Obesity Related Diseases and Disorders	2007-539329	11/1/2005	4926069	2/17/2012
0109JP4	Japan	Methods for Treating Obesity and Obesity Related Diseases and Disorders	2010-534004	11/14/2007		
0109KR1	Korea South	Methods for Treating Obesity and Obesity Related Diseases and Disorders	10-2007-7012269	11/1/2005	10-1123549	2/27/2012
0109KR4-LL	Korea South	Methods for Treating Obesity and Obesity Related Diseases and Disorders	10-2010-7012898	11/14/2007		
0109MX1	Mexico	Methods for Treating Obesity and Obesity Related Diseases and Disorders	2007/005274	11/1/2005	272502	12/8/2009
0109MX1-D1	Mexico	Methods for Treating Obesity and Obesity Related Diseases and Disorders	MX/A/2009/006801	6/22/2009		

0109MX4	Mexico	Methods for Treating Obesity and Obesity Related Diseases and Disorders	MX/A/2010/005345	11/14/2007		
0109NL1	Netherlands	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109NZ4	New Zealand	Methods for Treating Obesity and Obesity Related Diseases and Disorders	586124	11/14/2007		
0109SE1	Sweden	Methods for Treating Obesity and Obesity Related Diseases and Disorders	5820773.9	11/1/2005	1814590	4/8/2009
0109SG1	Singapore	Methods for Treating Obesity and Obesity Related Diseases and Disorders	200703120-6	11/1/2005	132715	11/30/2010
0109SG4	Singapore	Methods for Treating Obesity and Obesity Related Diseases and Disorders	201003400-7	11/14/2007		
0109US-CIP1	United States	Methods for Treating Obesity and Obesity Related Diseases and Disorders	11/940317	11/1/2005		
0109US-PRO1	United States	Methods for Treating Obesity and Associated Diseases and Disorders	60/624357	11/1/2004		
0109US-UTL1	United States	Methods for Treating Obesity and Obesity Related Diseases and Disorders	11/665675	11/1/2005		
0109VN4	Vietnam	Pharmaceutical Compositions for Treating Obesity or Reducing Body Weight	1-2010-01503	11/14/2007		
0109WO1	PCT	Methods for Treating Obesity and Obesity Related Diseases and Disorders	PCT/US2005/039686	11/1/2005		
0109WO4	PCT	Methods for Treating Obesity and Obesity Related Diseases and Disorders	PCT/US2007/084733	11/14/2007		
0109ZA1-LL	South Africa	Methods for Treating Obesity and Obesity Related Diseases and Disorders	2007/04239	11/1/2005	2007/04239	4/30/2008
0110AT1	Austria	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	E439140	8/12/2009
0110AU1	Australia	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	2006230602	3/31/2006	2006230602	10/28/2010
0110AU2	Australia	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	2006341375	10/4/2006		
0110BE1	Belgium	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009

		Disorders				
0110BR1	Brazil	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	PI0606466-3	3/31/2006		
0110CA1	Canada	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	2602261	3/31/2006		
0110CA2	Canada	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	2647568	10/4/2006		
0110CH1	Switzerland	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110CN1	China P.R.	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	200680019299.9	3/31/2006		
0110CN1-D1	China P.R.	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	201110220491.7	3/31/2006		
0110CN2	China P.R.	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	200680054122.2	10/4/2006		
0110DE1	Germany	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	6.02006E+11	8/12/2009
0110DK1	Denmark	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110EA1	Eurasia	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	200702126	3/31/2006	13121	2/26/2010
0110EP1	Europe	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110EP1-D1	Europe	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	9009392.3	3/31/2006		
0110EP1-D2	Europe	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	10008998.6	3/31/2006		
0110EP2	Europe	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6816288.2	10/4/2006		
0110ES1	Spain	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	2330671	8/12/2009
0110FI1	Finland	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009

0110FR1	France	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110GB1	Great Britain	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110GR1	Greece	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	3070484	8/12/2009
0110IL1	Israel	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	186200	3/31/2006		
0110IN1	India	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	7379/DELNP/2007	3/31/2006		
0110IT1	Italy	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110JP1	Japan	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	2008-504532	3/31/2006		
0110JP2	Japan	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	2009-502755	10/4/2006		
0110KR1	Korea South	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	10-2007-7025152	3/31/2006		
0110KR2	Korea South	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	10-2008-7023804	10/4/2006		
0110LU1	Luxembourg	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110MX1	Mexico	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	A/2007/012237	3/31/2006	273533	1/20/2010
0110MX2	Mexico	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	MX/A/2008/012666	10/4/2006	282182	12/16/2010
0110NL1	Netherlands	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110NZ1	New Zealand	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	561936	3/31/2006	561936	11/12/2009
0110NZ1-D1	New Zealand	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	578298	3/31/2006	578298	11/6/2010
0110NZ1-D2	New Zealand	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	578299	3/31/2006	578299	7/8/2010

		Disorders				
0110PH1	Philippines	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	1-2007-502140	3/31/2006	12007502140	9/5/2011
0110RU1	Russia	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	200702126	3/31/2006	13121	2/26/2010
0110SE1	Sweden	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	6749305.6	3/31/2006	1888094	8/12/2009
0110SG1	Singapore	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	200708850-3	3/31/2006	135798	4/30/2010
0110US1-CON1	United States	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	13/112290	3/31/2006		
0110US1-D1	United States	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	12/641733	3/31/2006		
0110US-PRO1	United States	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	60/667335	3/31/2005		
0110US-PRO2	United States	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	60/760583	1/20/2006		
0110US-UTL1	United States	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	11/910206	3/31/2006	7671023	3/2/2010
0110US-UTL2	United States	Amylin Agonists for Treating Cognitive Impairments	12/295259	10/4/2006		
0110WO1	PCT	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	PCT/US2006/012601	3/31/2006		
0110WO2	PCT	Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders	PCT/US2006/038919	10/4/2006		
0113AU1-LL	Australia	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	2006230420	3/31/2006	2006230420	3/8/2012
0113BR1	Brazil	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	PI0609595-0	3/31/2006		
0113CA1	Canada	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	2602584	3/31/2006		
0113CH1	Switzerland	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	6740117.4	3/31/2006	1871403	9/8/2010

0113CN1	China P.R.	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	2006800192236.0	3/31/2006	ZL200680019223	12/14/2011
0113DE1	Germany	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	6740117.4	3/31/2006	6.02006E+11	9/8/2010
0113EP1	Europe	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	6740117.4	3/31/2006	1871403	9/8/2010
0113EP1-D1	Europe	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	10008733.7	3/31/2006		
0113FR1	France	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	6740117.4	3/31/2006	1871403	9/8/2010
0113GB1	Great Britain	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	6740117.4	3/31/2006	1871403	9/8/2010
0113IN1	India	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	7383/DELNP/2007	3/31/2006		
0113JP1	Japan	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	2008-504396	3/31/2006		
0113KR1	Korea South	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	10-2007-7025124	3/31/2006		
0113MX1	Mexico	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	A/2007/012236	3/31/2006	291238	10/21/2011
0113MX1-D1	Mexico	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	MX/A/2011/008072	3/31/2006		
0113PCT	PCT	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	PCT/US2006/011768	3/31/2006		
0113US-DIV1	United States	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	12/964516	3/31/2006		
0113US-PRO	United States	Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders	60/675441	4/28/2005		
0113US-UTL1-LL	United States	Methods for Controlling Binge Eating Disorders	11/910214	3/31/2006	7879794	2/1/2011
0116US-PRO1	United States	Methods for Affecting Body Composition	61/055090	5/21/2008		
0116US-PRO2	United States	Methods for Affecting Body Composition	61/160956	3/17/2009		
0116US-UTL	United States	Methods for Affecting Body Composition Using Amylin Agonists	13/256779	3/17/2010		

0116WO1	PCT	Methods for Affecting Body Composition Using Amylin Agonists	PCT/US2010/027599	3/17/2010		
0117EP1	Europe	Amylin Agonist Compounds for Estrogen-Deficient Mammals	10762535.2	4/9/2010		
0117JP1-LL	Japan	Amylin Agonist Compounds for Estrogen-Deficient Mammals	2012-504907	4/10/2010		
0117US-PRO1	United States	Amylin Agonist Compounds for Estrogen-Deficient Mammals	61/168317	4/10/2009		
0117US-UTL	United States	Amylin Agonist Compounds for Estrogen-Deficient Mammals	13/263070	4/9/2010		
0117WO1	PCT	Amylin Agonist Compounds for Estrogen-Deficient Mammals	PCT/US2010/030625	4/9/2010		
0119US-PRO3	United States	Amylin-Calcitonin Chimeric Peptides Conjugated to Duration Enhancing Moieties	61/548404	10/18/2011		
0122US-PRO2	United States	Amylin Agonists for Treating Short Bowel Syndrome	61/531711	9/7/2011		
0123US-PRO1	United States	Amylin Peptides and Derivatives and Uses Thereof	61/489781	5/23/2011		
0123WO1	PCT	Amylin Peptides and Derivatives and Uses Thereof	PCT/US2012/39431	5/24/2012		
0124US-PRO1	United States	Long-acting Amylin Analog (Salmon Calcitonin) for the Treatment of Obesity	61/616732	3/28/2012		
0202US-CON1-LL	United States	Exendins, Exendin Agonists and Methods for Their Use	10/187051	6/28/2002	6989366	1/24/2006
0202US-CON2-LL	United States	Use of Exendins and Agonists Thereof for Lowering Plasma Lipid	10/966337	10/14/2004	7138375	11/21/2006
0202US-CON3	United States	Exendins, Exendin Agonists and Methods for Their Use	10/964887	10/15/2004	7115569	10/3/2006
0202US-CON4	United States	Exendins, Exendin Agonists and Methods for Their Use	11/368225	3/3/2006	7419952	9/2/2008
0202US-CON5	United States	Exendin Agonist Analogs to Treat Diabetes	12/201918	8/29/2008	7700549	4/20/2010
0204US-CON	United States	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	10/342014	1/13/2003		
0204US-CON1	United States	Treatment of Gestational Diabetes	11/282085	11/17/2005	7452858	11/18/2008
0204US-CON2-LL	United States	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	11/869013	10/9/2007		
0205JP-LL	Japan	Method and Composition for Enhanced Parenteral Nutrition	510445/1997	8/22/1996	3839485	8/11/2006
0205PCT	PCT	Method and Composition for Enhanced Parenteral Nutrition	PCT/US96/013615	8/22/1996		
0205US-CON1	United States	Method and Composition for Enhanced Parenteral Nutrition	09/749307	8/22/1996		

0205US-CON2-LL	United States	Method and Composition for Enhanced Parenteral Nutrition	10/842933	8/22/1996	7569540	8/4/2009
0205US-UTL	United States	Method and Composition for Enhanced Parenteral Nutrition	09/011940	8/22/1996	6852690	2/8/2005
0206AU-D1-LL	Australia	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	2003212050	5/7/1999	2003212050	6/1/2006
0206CA-LL	Canada	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	2334872	5/7/1999		
0206CN-LL	China P.R.	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	99809181.2	5/7/1999	ZL99809181.2	7/6/2005
0206EAPO	Eurasia	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	200100029	5/7/1999	4538	6/24/2004
0206IL-LL	Israel	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	140223	5/7/1999	140223	3/31/2011
0206NZ-D1-LL	New Zealand	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	527473	5/7/1999	527473	6/9/2005
0206NZ-LL	New Zealand	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	508823	5/7/1999	508823	2/9/2004
0206PCT	PCT	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	PCT/US99/010040	5/7/1999		
0206PL-LL	Poland	Glucagon-like Peptide-1 Improves B-cell Response to Glucose in Subjects with Impaired Glucose Tolerance (amended)	P345212	5/7/1999	195662	3/27/2007
0206US-PRO	United States	Glucagon-like Peptide-1 Improves the Ability of the B-cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	60/089044	6/12/1998		
0206US-UTL-LL	United States	Glucagon-like Peptide-1 Improves Beta-cell Response to Glucose in Subjects with Impaired Glucose Tolerance	09/719410	5/7/1999	7265087	9/4/2007
0207PCT	PCT	Human Appetite Control by Glucagon-like Receptor Binding Compounds	PCT/US99/005571	3/16/1999		
0207US-PRO	United States	Human Appetite Control by Glucagon-like Peptide Receptor Binding Compounds	60/078544	3/19/1998		
0207US-UTL	United States	Human Appetite Control by Glucagon-like Receptor Binding Compounds	09/646433	3/16/1999	6998387	2/14/2006
0210AU-LL	Australia	Treatment of Acute Coronary Syndrome with GLP-1	2001263230	5/18/2001	2001263230	6/23/2005

0210CA-LL	Canada	Treatment of Acute Coronary Syndrome with GLP-1	2407784	5/18/2001		
0210CN	China P.R.	Treatment of Acute Coronary Syndrome with GLP-1	1809663.8	5/18/2001		
0210JP	Japan	Treatment of Acute Coronary Syndrome with GLP-1	2001-585797	5/18/2001	4881533	12/9/2011
0210MX	Mexico	Treatment of Acute Coronary Syndrome with GLP-1	PA/A/2002/011339	5/18/2001	268291	7/14/2009
0210PCT	PCT	Treatment of Acute Coronary Syndrome with GLP-1	PCT/US01/15996	5/18/2001		
0210SG	Singapore	Treatment of Acute Coronary Syndrome with GLP-1	200208135-6	5/18/2001	92277	1/31/2005
0210US-DIV1-LL	United States	Treatment of Acute Coronary Syndrome with Exendin-4	10/322839	12/18/2002	7056887	6/6/2006
0210US-DIV2	United States	Treatment of Acute Coronary Syndrome with an Exendin	11/255279	10/20/2005		
0210US-DIV3	United States	Method of Performing Angioplasty with a GLP-1 Molecule	12/822165	6/23/2010	7981861	7/19/2011
0210US-PRO	United States	Treatment of Acute Coronary Syndrome with GLP-1	60/205239	5/19/2000		
0210US-UTL	United States	Treatment of Acute Coronary Syndrome with GLP-1	09/859804	5/18/2001	6706689	3/16/2004
0211AU-D1-LL	Australia	Treatment of Hibernating Myocardium or Pulmonary Congestion	2004229049	10/22/2001	2004229049	2/14/2008
0211AU-LL	Australia	Treatment of Hibernating Myocardium or Pulmonary Congestion	14618/02	10/22/2001	775663	11/25/2004
0211CA-LL	Canada	Treatment of Hibernating Myocardium with a GLP-1 Peptide	2395165	10/22/2001	2395165	5/22/2012
0211DE-LL	Germany	Treatment of Hibernating Myocardium with a GLP-1 Peptide	1983169.2	10/22/2001	60142351.8-08	6/9/2010
0211EP-LL	Europe	Treatment of Hibernating Myocardium with a GLP-1 Peptide	1983169.2	10/22/2001	1330261	6/9/2010
0211ES-LL	Spain	Treatment of Hibernating Myocardium with a GLP-1 Peptide	1983169.2	10/22/2001	2347137	6/9/2010
0211FR-LL	France	Treatment of Hibernating Myocardium with a GLP-1 Peptide	1983169.2	10/22/2001	1330261	6/9/2010
0211GB-LL	Great Britain	Treatment of Hibernating Myocardium with a GLP-1 Peptide	1983169.2	10/22/2001	1330261	6/9/2010
0211IT-LL	Italy	Treatment of Hibernating Myocardium with a GLP-1 Peptide	1983169.2	10/22/2001	1330261	6/9/2010
0211JP	Japan	Treatment of Hibernating Myocardium with a GLP-1 Peptide	2002-537336	10/22/2001	4480329	3/26/2010
0211MX-LL	Mexico	Treatment of Hibernating Myocardium with a GLP-1 Peptide	PA/A/2002/006118	10/22/2001	282091	12/14/2010
0211NZ-LL	New Zealand	Treatment of Hibernating Myocardium with a GLP-1 Peptide	519752	10/22/2001	519752	8/11/2005
0211US-CON1-LL	United States	Treatment of Diabetic Cardiomyopathy with a GLP-1 Peptide	12/945702	11/12/2010		

0211US-PRO1	United States	Treatment of Hibernating Myocardium with a GLP-1 Peptide	60/241834	10/20/2000		
0211US-PRO2	United States	Treatment of Hibernating Myocardium with a GLP-1 Peptide	60/242139	10/23/2000		
0211US-PRO3	United States	Treatment of Hibernating Myocardium and Diabetic Cardiomyopathy with a GLP-1 Peptide	60/245234	11/3/2000		
0211US-UTL	United States	Treatment of Hibernating Myocardium and Diabetic Cardiomyopathy with a GLP-1 Peptide	09/982978	10/22/2001	6894024	5/17/2005
0211WO	PCT	Treatment of Hibernating Myocardium with a GLP-1 Peptide	PCT/US01/32559	10/22/2001		
0212AU1-LL	Australia	Methods and Compositions for Treating Polycystic Ovary Syndrome	2003205135	1/14/2003	2003205135	5/1/2008
0212CA1	Canada	Methods and Compositions for Treating Polycystic Ovary Syndrome	2473927	1/14/2003		
0212DE1-LL	Germany	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	60338249.5	8/31/2011
0212DK1-LL	Denmark	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	1523325	8/31/2011
0212EP1-LL	Europe	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	1523325	8/31/2011
0212EP2	Europe	Methods and Compositions for Treating Polycystic Ovary Syndrome	3812761.9	7/30/2003		
0212ES1-LL	Spain	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	2372481	8/31/2011
0212FR1-LL	France	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	1523325	8/31/2011
0212GB1-LL	Great Britain	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	1523325	8/31/2011
0212IT1-LL	Italy	Methods and Compositions for Treating Polycystic Ovary Syndrome	3703804.9	1/14/2003	1523325	8/31/2011
0212NZ1-LL	New Zealand	Methods and Compositions for Treating Polycystic Ovary Syndrome	534611	1/14/2003	534611	8/14/2008
0212PCT1	PCT	Methods and Compositions for Treating Polycystic Ovary Syndrome	PCT/US2003/001109	1/14/2003		
0212PCT2	PCT	Methods and Compositions for Treating Polycystic Ovary Syndrome	PCT/US2003/23715	7/30/2003		

		Syndrome				
0212US-CIP1-LL	United States	Methods and Compositions for Treating Polycystic Ovary Syndrome	10/629649	7/30/2003	7105490	9/12/2006
0212US-DIV1-LL	United States	Methods and Compositions for Treating Polycystic Ovary Syndrome	11/518574	9/8/2006	7960341	6/14/2011
0212US-PRO	United States	Methods and Compositions for Treating Polycystic Ovary Syndrome	60/350395	1/22/2002		
0212US-UTL-LL	United States	Methods and Compositions for Treating Polycystic Ovary Syndrome	10/317126	12/11/2002	7105489	9/12/2006
0213AT1	Austria	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213AU1-D1-LL	Australia	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	2004240247	4/27/2000	2004240247	11/13/2008
0213AU1-LL	Australia	Metabolic intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	44935/00	4/27/2000	777019	1/20/2005
0213AU2-D1-LL	Australia	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	2004212547	5/1/2000	2004212547	7/3/2008
0213AU2-LL	Australia	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	46825/00	5/1/2000	774084	7/28/2005
0213BE1	Belgium	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213CA1-LL	Canada	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	2372947	4/27/2000		
0213CA2-LL	Canada	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	2368772	5/1/2000	2368772	11/15/2011
0213CH1	Switzerland	Metabolic Intervention with GLP-1 to improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213CY1	Cyprus	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213DE1	Germany	Metabolic Intervention with GLP-1 to improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	60016393.8	12/1/2004

0213DE2-LL	Germany	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	928616.2	5/1/2000	60035987.5-08	8/15/2007
0213DK1	Denmark	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213EP1	Europe	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213EP2-LL	Europe	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	928616.2	5/1/2000	1187628	8/15/2007
0213ES1	Spain	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	2233366	12/1/2004
0213ES2-LL	Spain	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	928616.2	5/1/2000	2290029	8/15/2007
0213FI1	Finland	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213FR1	France	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213FR2-LL	France	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	928616.2	5/1/2000	1187628	8/15/2007
0213GB1	Great Britain	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213GB2-LL	Great Britain	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	928616.2	5/1/2000	1187628	8/15/2007
0213GR1	Greece	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	3052781	12/1/2004
0213IE1	Ireland	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213IL1-LL	Israel	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	145830	4/27/2000	145830	3/31/2011
0213IL2-LL	Israel	Metabolic Intervention with GLP-1 or its Biologically Active	145829	5/1/2000	145829	2/1/2011

		Analogues to Improve the Function of the Ischemic and Reperfused Brain				
0213IT1	Italy	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213IT2-LL	Italy	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	928616.2	5/1/2000	1187628	8/15/2007
0213LU1	Luxembourg	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213MC1	Monaco	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213MX1	Mexico	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	PA/A/2001/010859	4/27/2000	232315	11/23/2005
0213MX2-LL	Mexico	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	PA/A/2001/010937	5/1/2000	252642	12/17/2007
0213NL1	Netherlands	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213NO1-LL	Norway	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	2001-5294	4/27/2000	325601	6/23/2008
0213NZ1-LL	New Zealand	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	514610	4/27/2000	514610	5/10/2004
0213NZ2-LL	New Zealand	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	514609	5/1/2000	514609	7/5/2004
0213PCT1	PCT	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	PCT/US00/11251	4/27/2000		
0213PCT2	PCT	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	PCT/US00/11652	5/1/2000		
0213PT1	Portugal	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004
0213SE1	Sweden	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	926404.5	4/27/2000	1173197	12/1/2004

0213US-CIP1-LL	United States	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	09/302596	4/30/1999	6284725	9/4/2001
0213US-CIP3-LL	United States	Compositions and Methods for Treating Peripheral Vascular Disease	10/091258	3/5/2002	7259136	8/21/2007
0213US-CON1	United States	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Skeletal Muscle Tissue	09/953021	9/11/2001		
0213US-CON3-LL	United States	Compositions and Methods for Treating Peripheral Vascular Disease	11/198527	8/5/2005	7888314	2/15/2011
0213US-DIV1-LL	United States	Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	09/851738	5/9/2001	6982248	1/3/2006
0213US-PRO	United States	GLP-1 Therapy for Myocardial Infarction	60/103498	10/8/1998		
0213US-RE2-LL	United States	Metabolic Intervention with GLP-1 or its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain	10/913309	8/6/2004	RE41288	4/27/2010
0217PCT	PCT	Prevention and Treatment of Cardiac Arrhythmias	PCT/US2003/40504	12/17/2003		
0217US-D1-LL	United States	Prevention and Treatment of Cardiac Arrhythmias	12/750575	3/30/2010		
0217US-PRO	United States	GLP-1 for Prevention of Cardiac Arrhythmias	60/434508	12/17/2002		
0217US-UTL-LL	United States	Treatment of Cardiac Arrhythmias with GLP-1 Receptor Ligands	10/740146	12/17/2003	7790681	9/7/2010
0218EP-LL	Europe	Compositions for the Treatment and Prevention of Nephropathy	3813809.5	12/19/2003		
0218PCT	PCT	Compositions for the Treatment and Prevention of Nephropathy	PCT/US2003/040713	12/19/2003		
0218US-PRO	United States	GLP-1 for Treatment of Nephropathy	60/434888	12/19/2002		
0222US-CON1-LL	United States	Pharmaceutical Compositions Containing Exendins	10/894999	7/19/2004	7297761	11/20/2007
0222US-CON2-LL	United States	Exendins and Exendin Agonists for Weight Reduction and Obesity	10/895909	7/20/2004	7741269	6/22/2010
0222US-CON3-LL	United States	Exendins and Exendin Agonists for Eating Disorders	12/766195	4/23/2010		
0223US-CON1-LL	United States	Exendin Pharmaceutical Compositions	10/896244	7/20/2004	7521423	4/21/2009
0223US-CON2-LL	United States	Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility	12/353861	1/14/2009	8026210	9/27/2011
0223US-CON3-LL	United States	Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility	13/226975	9/7/2011		

0226AU-LL	Australia	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	2005323063	12/22/2005	2005323063	5/12/2011
0226CA-LL	Canada	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	2599594	12/22/2005		
0226EP-LL	Europe	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	5857195.1	12/22/2005		
0226PCT	PCT	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	PCT/US2005/046788	12/22/2005		
0226US-CON1-LL	United States	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	11/857951	9/19/2007		
0226US-PRO	United States	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	60/639124	12/24/2004		
0226US-UTL	United States	Use of GLP-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis	11/313763	12/22/2005		
0227DE-LL	Germany	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	6740942.5	4/11/2006	1888103	3/21/2012
0227DK-LL	Denmark	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	6740942.5	4/11/2006	1888103	3/21/2012
0227EP-LL	Europe	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	6740942.5	4/11/2006	1888103	3/21/2012
0227FR-LL	France	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	6740942.5	4/11/2006	1888103	3/21/2012
0227GB-LL	Great Britain	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	6740942.5	4/11/2006	1888103	3/21/2012
0227PCT	PCT	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	PCT/US2006/013949	4/11/2006		
0227US-PRO	United States	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	60/669876	4/11/2005		
0227US-UTL-LL	United States	Use of GLP-1, Exendin and Agonists Thereof to Delay or Prevent Cardiac Remodeling	11/910730	4/11/2006		
0228US-PRO	United States	New Uses of Glucoregulatory Proteins	60/709647	8/19/2005		
0228US-UTL-LL	United States	Methods for Treating Liver Diseases with Exendin-4	12/063712	8/21/2006		

0228WO1	PCT	New Uses of Glucoregulatory Proteins	PCT/US2006/032661	8/21/2006		
0229AU1-D1-LL	Australia	Exendin for Treating Diabetes and Reducing Body Weight	2011200663	8/18/2006		
0229AU1-LL	Australia	Exendin for Treating Diabetes and Reducing Body Weight	2006283517	8/18/2006	2006283517	3/17/2011
0229BR1-LL	Brazil	Exendin for Treating Diabetes and Reducing Body Weight	PI0615358-5	8/18/2006		
0229CA1-LL	Canada	Exendin for Treating Diabetes and Reducing Body Weight	2619426	8/18/2006		
0229CN1-LL	China P.R.	Exendin for Treating Diabetes and Reducing Body Weight	200680038544.0	8/18/2006		
0229EA1-LL	Eurasia	Exendin for Treating Diabetes and Reducing Body Weight	2008110504	8/18/2006	2421237	6/20/2011
0229EP1-D1-LL	Europe	Exendin for Treating Diabetes and Reducing Body Weight	10016112.4	8/18/2006		
0229EP1-LL	Europe	Exendin for Treating Diabetes and Reducing Body Weight	6801867	8/18/2006		
0229IL1-LL	Israel	Exendin for Treating Diabetes and Reducing Body Weight	189607	8/18/2006		
0229JP1-LL	Japan	Exendin for Treating Diabetes and Reducing Body Weight	2008-527170	8/18/2006		
0229KR1-LL	Korea South	Exendin for Treating Diabetes and Reducing Body Weight	10-2008-7006560	8/18/2006	10-1059279	8/18/2011
0229MX1-LL	Mexico	Exendin for Treating Diabetes and Reducing Body Weight	2008/002370	8/18/2006		
0229NZ1-D1-LL	New Zealand	Exendin for Treating Diabetes and Reducing Body Weight	593461	8/18/2006		
0229NZ1-LL	New Zealand	Exendin for Treating Diabetes and Reducing Body Weight	566763	8/18/2006	566763	10/10/2011
0229RU1-LL	Russia	Exendin for Treating Diabetes and Reducing Body Weight	2008110504	8/18/2006	2421237	6/20/2011
0229SG1-LL	Singapore	Exendin for Treating Diabetes and Reducing Body Weight	200801274-2	8/18/2006		
0229US-CON1-LL	United States	Methods for Treating Diabetes and Reducing Body Weight	13/084757	4/12/2011		
0229US-PRO	United States	Methods for Treating Diabetes and Reducing Body Weight	60/709604	8/19/2005		
0229US-PRO2	United States	Methods for Treating Diabetes and Reducing Body Weight	60/779216	3/3/2006		
0229US-UTL1	United States	Methods for Treating Diabetes and Reducing Body Weight	12/064216	8/18/2006		
0229WO1	PCT	Exendin for Treating Diabetes and Reducing Body Weight	PCT/US2006/032354	8/18/2006		
0233AU1	Australia	Compositions and Methods for Treatment of Congestive Heart Failure	2007267833	5/25/2007		

0233CA1	Canada	Compositions and Methods for Treatment of Congestive Heart Failure	2652907	5/25/2007		
0233EP1	Europe	Compositions and Methods for Treatment of Congestive Heart Failure	7777280.4	5/25/2007		
0233IL1	Israel	Compositions and Methods for Treatment of Congestive Heart Failure	194975	5/25/2007		
0233IN1	India	Compositions and Methods for Treatment of Congestive Heart Failure	10246/DELNP/2008	5/25/2007		
0233JP1	Japan	Compositions and Methods for Treatment of Congestive Heart Failure	2009-513202	5/25/2007		
0233US-PRO	United States	Methods for Treating Diabetes and Reducing Body Weight	60/808810	5/26/2006		
0233US-UTL1	United States	Novel Exendin and GLP-1 Peptides and Their Uses	12/301199	5/25/2007		
0233WO1	PCT	Compositions and Methods for Treatment of Congestive Heart Failure	PCT/US2007/012499	5/25/2007		
0241EP1-LL	Europe	Exendins to Lower Cholesterol and Triglycerides	9751513.4	5/20/2009		
0241US-PRO1	United States	Exendins to Lower Cholesterol and Triglycerides	61/054883	5/21/2008		
0241US-UTL-LL	United States	Exendins to Lower Cholesterol and Triglycerides	12/992060	5/20/2009		
0241WO1	PCT	Exendins to Lower Cholesterol and Triglycerides	PCT/US2009/044727	5/20/2009		
0242EP1-LL	Europe	GLP-1 Receptor Agonist Bioassays	9751243.8	5/15/2009		
0242IN1-LL	India	GLP-1 Receptor Agonist Bioassays	8188/DELNP/2010	5/15/2009		
0242JP1-LL	Japan	GLP-1 Receptor Agonist Bioassays	2011-510592	5/15/2009		
0242US-PRO1	United States	Exendin Bioassays	61/055842	5/23/2008		
0242US-UTL-LL	United States	GLP-1 Receptor Agonist Bioassays	12/990693	5/15/2009		
0242WO1	PCT	GLP-1 Receptor Agonist Bioassays	PCT/US2009/044135	5/15/2009		
0243US-PRO1	United States	C-Terminal Amidation of Polypeptides	61/382391	9/13/2010		
0243WO1-LL	PCT	C-Terminal Amidation of Polypeptides	PCT/US2011/050754	9/8/2011		
0244EP1	Europe	N-Terminus Conformationally Constrained GLP-1 Receptor Agonist Compounds	10764834.7	3/26/2010		

0244US-PRO1	United States	N-Terminus Conformationally Constrained GLP-1 Receptor Agonist Compounds	61/165604	4/1/2009		
0244US-UTL	United States	N-Terminus Conformationally Constrained GLP-1 Receptor Agonist Compounds	13/260702	3/16/2010		
0244WO1	PCT	N-Terminus Conformationally Constrained GLP-1 Receptor Agonist Compounds	PCT/US2010/28883	3/26/2010		
0246US-PRO1	United States	GLP-1 Receptor Agonist Compounds	61/368522	7/28/2010		
0246WO	PCT	GLP-1 Receptor Agonist Compounds Having Stabilized Regions	PCT/US2011/045614	7/27/2011		
0249US-PRO1	United States	GLP-1 Receptor Agonists to Treat Pancreatitis	61/352906	6/9/2010		
0249US-UTL-LL	United States	GLP-1 Receptor Agonists to Treat Pancreatitis	13/155211	6/7/2011		
0249WO1-LL	PCT	GLP-1 Receptor Agonists to Treat Pancreatitis	PCT/US2011/039494	6/7/2011		
0250US-PRO1	United States	Engineered Polypeptides Having Enhanced Duration of Action	61/387391	9/28/2010		
0250US-PRO2	United States	Engineered Polypeptides Having Enhanced Duration of Action	61/422085	12/10/2010		
0250WO1	PCT	Engineered Polypeptides Having Enhanced Duration of Action	PCT/US2011/053770	9/28/2011		
0253US-PRO1-LL	United States	Peptide Combinations and Methods of Use	61/552896	10/28/2011		
0263US-PRO1	United States	Engineered Polypeptides Having Enhanced Duration of Action with Reduced Immunogenicity	61/505982	7/8/2011		
0263US-PRO2	United States	[Engineered Polypeptides Having Enhanced Duration of Action with Reduced Immunogenicity] [Exendin PEP ABDs]	61/585577	1/11/2012		
0263WO	WO	Engineered Polypeptides Having Enhanced Duration of Action with Reduced Immunogenicity	To Be Determined	7/3/2012		
0264US-PRO1	United States	GLP-1 Reactions with Transglutaminases	61/637393	4/24/2012		
0265US-PRO1	United States	Transmucosal Delivery of Engineered Polypeptides	61/616961	3/28/2012		
0401AU-D1-LL	Australia	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	2007200224	12/14/2001	2007200224	1/14/2010
0401AU-LL	Australia	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	2002230843	12/14/2001	2002230843	2/1/2007
0401BR-LL	Brazil	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	PI0116206-3	12/14/2001		

0401CA-LL	Canada	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	2431800	12/14/2001		
0401CN-LL	China P.R.	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	1822647.7	12/14/2001	ZL01822647.7	3/2/2011
0401DE-LL	Germany	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	1991093.4	12/14/2001	60140693.1-08	12/2/2009
0401EP-D1-LL	Europe	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	9010965.3	12/14/2001		
0401EP-LL	Europe	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	1991093.4	12/14/2001	1349563	12/2/2009
0401FR-LL	France	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	1991093.4	12/14/2001	1349563	12/2/2009
0401GB-LL	Great Britain	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	1991093.4	12/14/2001	1349563	12/2/2009
0401MX-LL	Mexico	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	PA/A/2003/005388	12/14/2001	273272	1/12/2010
0401PCT	PCT	Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders	PCT/US01/48336	12/14/2001		
0401RU-LL	Russia	Method for Reducing Nutrient Availability, Method for Suppressing Appetite	2003121230	12/14/2001	2275207	4/27/2006
0401US-PRO	United States	Peptide YY and Peptide YY Agonists for Treatment of Obesity, Diabetes and Other Metabolic Disorders	60/256216	12/14/2000		
0401US-UTL-LL	United States	Peptide YY and Peptide YY Agonists for Treatment of Obesity, Diabetes and Other Metabolic Disorders	10/016969	12/14/2001		
0406AU	Australia	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	2005211776	2/11/2005		
0406AU2-LL	Australia	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	2005316524	12/12/2005	2005316524	4/26/2012
0406BR2-LL	Brazil	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	PI0518559-9	12/12/2005		
0406CA	Canada	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	2555894	2/11/2005		
0406CA2-LL	Canada	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods	2588594	12/12/2005		

		Comprising the Same				
0406CN	China P.R.	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	200580004687.5	2/11/2005		
0406CN2-LL	China P.R.	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	200580047198.8	12/12/2005		
0406EP	Europe	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	5722950.2	2/11/2005		
0406EP2-D1-LL	Europe	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	11150814.9	12/12/2005		
0406EP2-LL	Europe	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	5854234.1	12/12/2005		
0406EP-D1	Europe	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	10013127.5	2/11/2005		
0406EP-D2	Europe	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	10013143.2	2/11/2005		
0406IL	Israel	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	177403	2/11/2005		
0406IL2	Israel	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	183405	12/12/2005		
0406IN	India	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	04567/DELNP/06	2/11/2005		
0406IN2-LL	India	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	04557/DELNP/2007	12/12/2005		
0406JP	Japan	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	2006-553254	2/11/2005		
0406JP2-LL	Japan	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	2007-545739	12/12/2005		
0406KR2-LL	Korea South	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	10-2007-7015964	12/12/2005		
0406MX2	Mexico	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	2007/006830	12/12/2005	287229	6/6/2011
0406NZ2-LL	New Zealand	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	555533	12/12/2005	555533	7/8/2010

0406PCT	PCT	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	PCT/US2005/004351	2/11/2005		
0406PCT2	PCT	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	PCT/US2005/045471	12/12/2005		
0406PH2-D1-LL	Philippines	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	1-2010-520572	12/12/2005		
0406PH2-LL	Philippines	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	1-2007-501212	12/12/2005	1-2007-501212	4/18/2011
0406RU2-LL	Russia	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	2007126653	12/12/2005	2427586	8/27/2011
0406SG2-D2-LL	Singapore	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	201200776-1	12/12/2005		
0406US-CIP	United States	Pancreatic Polypeptide Family Motifs and Polypeptides and Methods Comprising the Same	11/301744	12/12/2005	7723471	5/25/2010
0406US-CON1-LL	United States	Pancreatic Polypeptide Family Motifs and Polypeptides and Methods Comprising the Same	12/640352	12/17/2009		
0406US-PRO	United States	PYY Analog Polypeptide Compositons and Methods	60/543406	2/11/2004		
0406US-UTL	United States	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	11/055098	2/11/2005		
0406WO	PCT					
0410US-PRO1	United States	Pharmaceutical Compositions Comprising Microcrystalline Suspensions of Y Receptor Agonists for Extended Delivery of Such, and Methods and Uses for the Same	61/363200	7/9/2010		
0410WO1	PCT	Microcrystalline Y Receptor Agonists	PCT/US2011/043420	7/8/2011		
0501EP1-LL	Europe	Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins	4754133.9	5/28/2004		
0501PCT	PCT	Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins	PCT/US2004/017456	5/28/2004		
0501PCT2	PCT	Improved Transmucosal Delivery of Peptides and Proteins	PCT/US2005/001440	1/12/2005		
0501US-PRO	United States	Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins	60/474233	5/30/2003		
0501US-UTL1-LL	United States	Methods and Compositions for Enhanced Transmucosal Delivery	10/559595	5/28/2004	8008255	8/30/2011

		of Peptides and Proteins				
0501US-UTL2-LL	United States	Transmucosal Delivery of Peptides and Proteins	11/628123	1/12/2005		
0502AU-LL	Australia	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	2006235183	4/6/2006	2006235183	5/26/2011
0502CA-LL	Canada	Peptide and Protein Formulations with Improved Stability [as issued by CA Patent Office]	2802249	4/6/2006		
0502CN-LL	China P.R.	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	200680019970.X	4/6/2006	ZL200680019970	11/2/2011
0502DE-LL	Germany	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	6740736.1	4/6/2006	6.02006E+11	5/18/2011
0502EP-LL	Europe	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	6740736.1	4/6/2006	1909824	5/18/2011
0502ES-LL	Spain	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	6740736.1	4/6/2006	2365410	5/18/2011
0502FR-LL	France	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	6740736.1	4/6/2006	1909824	5/18/2011
0502GB-LL	Great Britain	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	6740736.1	4/6/2006	1909824	5/18/2011
0502IN-LL	India	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	7498/DELNP/2007	4/6/2006		
0502IT-LL	Italy	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	6740736.1	4/6/2006	1909824	5/18/2011
0502PCT	PCT	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	PCT/US2006/013073	4/6/2006		
0502US-PRO	United States	Peptide and Protein Formulations with Improved Stability	60/669353	4/8/2005		
0502US-UTL-LL	United States	Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent	11/910723	4/6/2006		
0504NO1	Norway	Intranasal Administration of Glucose-Regulating Peptides	2006 3436	12/17/2004		
0504US-PRO1	United States	Intranasal Administration of Glucose-Regulating peptides	60/532337	12/26/2003		
0504WO1	PCT	Intranasal Administration of Glucose-Regulating Peptides	PCT/US2004/043312	12/17/2004		
0601AU1	Australia	GIP Analog and Hybrid Polypeptides with Selectable Properties	2006213607	2/10/2006		

0601BR1	Brazil	GIP Analog and Hybrid Polypeptides with Selectable Properties	PI0606992-4	2/10/2006		
0601CA2-LL	Canada	DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties	2660835	8/17/2007		
0601EP1	Europe	GIP Analog and Hybrid Polypeptides with Selectable Properties	6734933.2	2/10/2006		
0601EP1-D1	Europe	GIP Analog and Hybrid Polypeptides with Selectable Properties	11176631.7	2/10/2006		
0601EP1-D2	Europe	GIP Analog and Hybrid Polypeptides with Selectable Properties	11176629.1	2/10/2006		
0601EP2-LL	Europe	DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties	7837095.4	8/17/2007		
0601IL1	Israel	GIP Analog and Hybrid Polypeptides with Selectable Properties	185563	2/10/2006		
0601IN1	India	GIP Analog and Hybrid Polypeptides with Selectable Properties	6776/DELNP/2007	2/10/2006		
0601IN2-LL	India	DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties	1770/DELNP/2009	8/17/2007		
0601JP1	Japan	GIP Analog and Hybrid Polypeptides with Selectable Properties	2007-555314	2/10/2006		
0601JP2	Japan	DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties	2009-524707	8/17/2007		
0601KR1	Korea South	GIP Analog and Hybrid Polypeptides with Selectable Properties	10-2007-7020688	2/10/2006		
0601NO1	Norway	GIP Analog and Hybrid Polypeptides with Selectable Properties	20074545	2/10/2006		
0601PCT1	PCT	GIP Analog and Hybrid Polypeptides with Selectable Properties	PCT/US2006/005020	2/10/2006		
0601PCT2	PCT	DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties	PCT/US2007/018415	8/17/2007		
0601US-CIP1	United States	GIP Analog and Hybrid Polypeptides with Selectable Properties	11/507081	8/17/2006		
0601US-CIP2	United States	GIP Analog and Hybrid Polypeptides with Selectable Properties	11/840921	8/17/2007		
0601US-PRO	United States	Novel GIP Analogs and Their Uses	60/652662	2/11/2005		
0601US-PRO2	United States	Novel GIP Analogs and Their Uses	60/653433	2/15/2005		
0601US-PRO3	United States	Novel GIP Analogs and Their Uses	60/707244	8/11/2005		
0601US-PRO4	United States	Novel GIP Analogs and Their Uses	60/709320	8/17/2005		
0601US-UTL1	United States	GIP Hybrid Polypeptides with Selectable Properties	11/816095	2/10/2006		

0601US-UTL2-LL	United States	DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties	12/377856	8/17/2006		
0701AU1	Australia	Hybrid Polypeptides with Selectable Properties	2005211755	2/11/2005	2005211755	
0701AU2-LL	Australia	Hybrid Polypeptides with Selectable Properties	2006279680	8/11/2006		
0701BR1	Brazil	Hybrid Polypeptides with Selectable Properties	PI0507594-7	2/11/2005		
0701BR2-LL	Brazil	Hybrid Polypeptides with Selectable Properties	PI0614649-0	8/11/2006		
0701CA1	Canada	Hybrid Polypeptides with Selectable Properties	2555877	2/11/2005		
0701CA2-LL	Canada	Hybrid Polypeptides with Selectable Properties	2617649	8/11/2006		
0701CN1	China P.R.	Hybrid Polypeptides with Selectable Properties	200580012009.3	2/11/2005	ZL200580012009	5/4/2011
0701CN1-D1	China P.R.	Hybrid Polypeptides with Selectable Properties	201110061194.2	3/4/2011		
0701CN2-LL	China P.R.	Hybrid Polypeptides with Selectable Properties	200680037664.9	8/11/2006		
0701EA2-LL	Eurasia	Hybrid Polypeptides with Selectable Properties	200800548	8/11/2006	14647	12/30/2010
0701EP1	Europe	Hybrid Polypeptides with Selectable Properties	5722892.6	2/11/2005		
0701EP1-D1	Europe	Hybrid Polypeptides with Selectable Properties	11176632.5	2/11/2005		
0701EP1-D2	Europe	Hybrid Polypeptides with Selectable Properties	11176630.9	2/11/2005		
0701EP1-D3	Europe	Hybrid Polypeptides with Selectable Properties	11176627.5	2/11/2005		
0701EP2	Europe	Hybrid Polypeptides with Selectable Properties	6801467.9	8/11/2006		
0701EP2-D1-LL	Europe	Hybrid Polypeptides with Selectable Properties	10012149	9/30/2010		
0701EP2-D2-LL	Europe	Hybrid Polypeptides with Selectable Properties	10012633.3	9/30/2010		
0701IL1	Israel	Hybrid Polypeptides with Selectable Properties	177229	2/11/2005		
0701IL2-LL	Israel	Hybrid Polypeptides with Selectable Properties	188937	8/11/2006		
0701IN1	India	Hybrid Polypeptides with Selectable Properties	4531/DELNP/2006	2/11/2005		
0701IN1-D1	India	Hybrid Polypeptides with Selectable Properties	3921/DELNP/2012	2/11/2005		
0701IN2	India	Hybrid Polypeptides with Selectable Properties	1175/DELNP/2008	8/11/2006		

0701JP1	Japan	Hybrid Polypeptides with Selectable Properties	2006-553217	2/11/2005		
0701JP1-D1	Japan	Hybrid Polypeptides with Selectable Properties	2011-137394	2/11/2005		
0701JP2	Japan	Hybrid Polypeptides with Selectable Properties	2008-526290	8/11/2006		
0701JP2-D1	Japan	Hybrid Polypeptides with Selectable Properties	2011-137014	8/11/2006		
0701KR1	Korea South	Hybrid Polypeptides with Selectable Properties	10-06-7018391	2/11/2005		
0701KR1-D1	Korea South	Hybrid Polypeptides with Selectable Properties	10-2012-7004103	2/11/2005		
0701KR2-LL	Korea South	Hybrid Polypeptides with Selectable Properties	10-2008-7005846	8/11/2006		
0701MX1	Mexico	Hybrid Polypeptides with Selectable Properties	2006/009239	2/11/2005	294408	1/6/2012
0701MX2-D1-LL	Mexico	Hybrid Polypeptides with Selectable Properties	MX/A/2011/008147	8/11/2006		
0701MX2-LL	Mexico	Hybrid Polypeptides with Selectable Properties	2008/002028	8/11/2006	296800	3/7/2012
0701NZ1	New Zealand	Hybrid Polypeptides with Selectable Properties	548978	2/11/2005	548978	2/11/2010
0701NZ1-D1	New Zealand	Hybrid Polypeptides with Selectable Properties	579621	2/11/2005	579621	7/11/2011
0701NZ1-D2	New Zealand	Hybrid Polypeptides with Selectable Properties	591653	3/10/2011		
0701NZ2	New Zealand	Hybrid Polypeptides with Selectable Properties	565788	8/11/2006		
0701NZ2-D1-LL	New Zealand	Hybrid Polypeptides with Selectable Properties	594603	8/11/2006		
0701PCT1	PCT	Hybrid Polypeptides with Selectable Properties	PCT/US2005/004178	2/11/2005		
0701PCT2	PCT	Hybrid Polypeptides with Selectable Properties	PCT/US2006/031724	8/11/2006		
0701RU1	Russia	Hybrid Polypeptides with Selectable Properties	2006132294	2/11/2005	2378285	1/10/2010
0701RU2-LL	Russia	Hybrid Polypeptides with Selectable Properties	200800548	8/11/2006	14647	12/30/2010
0701SG1	Singapore	Hybrid Polypeptides with Selectable Properties	200605210-4	2/11/2005		
0701SG2	Singapore	Hybrid Polypeptides with Selectable Properties	200800927-6	8/11/2006		
0701SG2-D1-LL	Singapore	Hybrid Polypeptides with Selectable Properties	201008263-4	8/11/2006		
0701US-CIP1	United States	Hybrid Polypeptides with Selectable Properties	11/201664	8/11/2005		
0701US-CIP2	United States	Hybrid Polypeptides Having Glucose Lowering Activity	11/206903	8/17/2005	8076288	12/13/2011

0701US-CON2	United States	Hybrid Polypeptides With Selectable Properties	13/323608	12/12/2011		
0701US-UTL1	United States	Hybrid Polypeptides with Selectable Properties	11/055093	2/11/2005		
0701US-UTL2-LL	United States	Hybrid Polypeptides with Selectable Properties	12/063420	8/11/2006		
0701ZA1	South Africa	Hybrid Polypeptides with Selectable Properties	2006/07190	2/11/2005	2006/07190	11/28/2007
0701ZA2-LL	South Africa	Hybrid Polypeptides with Selectable Properties	2008/01138	8/11/2006	2008/01138	12/31/2008
0703AU1	Australia	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703BR1	Brazil	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703CA1	Canada	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703CN1	China P.R.	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703EP1	Europe	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703IL1	Israel	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703IN1	India	Polypeptide Conjugates	4359/DELNP/2012	11/23/2010		
0703JP1	Japan	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703KR1	Korea South	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703MX1	Mexico	Polypeptide Conjugate	MX/A/2012/005912	11/23/2010		
0703NZ1	New Zealand	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703RU1	Russia	Polypeptide Conjugates	[Anticipated Filing]	11/23/2010		
0703US-PRO1	United States	Polypeptide Conjugate	61/263752	11/23/2009		
0703US-UTL1	United States	Polypeptide Conjugate	13/511201	11/23/2010		
0703WO1	PCT	Polypeptide Conjugates	PCT/US2010/057890	11/23/2010		
0705US-PRO1	United States	Long-Duration Dual Hormone Conjugates	61/489951	5/25/2011		
0705WO1	PCT	Long Duration Dual Hormone Conjugates	PCT/US2012/39440	5/24/2012		
0708US-PRO1	United States	Use of GLP-1R-HuSeal Phybids in the Treatment of Non-Alcoholic Steatohaptatitis	61/616906	3/28/2012		

0901PCT-GY	PCT	Polyoxime Compounds and Their Preparation	PCT/IB94/00093	5/5/1994		
0901US-DIV-GY	United States	Polyoxime Compounds and Their Preparation	08/537928	5/5/1994	6217873	4/17/2001
0904CA-GY	Canada	Polypeptide and Protein Derivatives and Process for Their Preparation	535860	4/29/1987	1341053	7/18/2000
0904US-UTL8-GY	United States	Polypeptide and Protein Derivatives and Process for Their Preparation	08/241667	5/12/1994	6673347	1/6/2004
0928US-CIP2-GY	United States	Lipid Matrix-Assisted Chemical Ligation and Synthesis of Membrane Polypeptides	09/384302	8/26/1999	6451543	9/27/2002
0928US-DIV-GY	United States	Lipid Matrix-Assisted Chemical Ligation and Synthesis of Membrane Polypeptides	10/207330	7/30/2002	7482425	1/27/2009
0939DE-GY	Germany	Pseudo* Native Chemical Ligation*	1952657.3	7/12/2001	60144188.5-08	3/9/2011
0939EP-GY	Europe	Pseudo* Native Chemical Ligation*	1952657.3	7/12/2001	1315513	3/9/2011
0939ES-GY	Spain	Pseudo* Native Chemical Ligation*	1952657.3	7/12/2001	2360203	3/9/2011
0939FR-GY	France	Pseudo* Native Chemical Ligation*	1952657.3	7/12/2001	1315513	3/9/2011
0939GB-GY	Great Britain	Pseudo* Native Chemical Ligation*	1952657.3	7/12/2001	1315513	3/9/2011
0939IT-GY	Italy	Pseudo* Native Chemical Ligation*	1952657.3	7/12/2001	1315513	3/9/2011
0939US-UTL-GY	United States	Pseudo* Native Chemical Ligation*	10/332386	7/12/2001	7030218	4/18/2006
0940PCT-GY	PCT	Displaceable Linker Solid Phase Chemical Ligation	PCT/US2004/015435	5/17/2004		
0940US-PRO-GY	United States	Displaceable Linker Solid Phase Chemical Ligation	60/473294	5/22/2003		
0944EP-GY	Europe	Water Soluble Thioester and Selenoester Compounds and Methods for Making and Using Same	3808599.9	12/30/2003		
0944PCT-GY	PCT	Water Soluble Thioester and Selenoester Compounds and Methods for Making and Using Same	PCT/US2003/041542	12/30/2003		
0944US-PRO-GY	United States	Water Soluble Thioester and Selenoester Compounds and Methods for Making and Using Same	60/437285	12/30/2002		
0944US-UTL-GY	United States	Water Soluble Thioester and Selenoester Compounds and Methods for Making and Using Same	10/541078	12/30/2003	8034900	10/11/2011
0949AT-GP	Austria	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006

0949BE-GP	Belgium	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949CH-GP	Switzerland	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949DE-GP	Germany	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	60303314.8	1/18/2006
0949EP-GP	Europe	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949FR-GP	France	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949GB-GP	Great Britain	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949IE-GP	Ireland	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949JP-GP	Japan	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	2004-521045	6/9/2003	4327718	6/19/2009
0949LU-GP	Luxembourg	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949MC-GP	Monaco	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949NL-GP	Netherlands	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949PCT-GP	PCT	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	PCT/IB2003/005473	6/9/2003		
0949SE-GP	Sweden	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	3764091.9	6/9/2003	1511760	1/18/2006
0949US-PRO-GP	United States	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	60/387925	6/10/2002		
0949US-UTL-GP	United States	Carboxy Protection Strategies for Acidic C-terminal Amino Acids in Chemical Ligation of Oligopeptides	10/517392	6/9/2003	7566597	7/28/2009
0950DE-GP	Germany	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	3760111.9	6/9/2003	60331437.6	2/24/2010
0950EP-GP	Europe	Post-Cleavage Sulfur Deprotection for Convergent Protein	3760111.9	6/9/2003	1529056	2/24/2010

		Synthesis by Chemical Ligation				
0950ES-GP	Spain	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	3760111.9	6/9/2003	2340376	2/24/2010
0950FR-GP	France	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	3760111.9	6/9/2003	1529056	2/24/2010
0950GB-GP	Great Britain	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	3760111.9	6/9/2003	1529056	2/24/2010
0950IE--GP	Ireland	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	3760111.9	6/9/2003	1529056	2/24/2010
0950IT-GP	Italy	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	3760111.9	6/9/2003	1529056	2/24/2010
0950JP-GP	Japan	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	2004-513428	6/9/2003	4559219	7/30/2010
0950PCT-GP	PCT	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	PCT/IB2003/05087	6/9/2003		
0950US-PRO1-GP	United States	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	60/387803	6/10/2002		
0950US-PRO2-GP	United States	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	60/407530	8/30/2002		
0950US-UTL-GP	United States	Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation	10/516118	6/9/2003	7781488	8/24/2010
0951AT-GP	Austria	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951BE-GP	Belgium	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951CH-GP	Switzerland	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951DE-GP	Germany	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	60206684.1	1/11/2006
0951EP-GP	Europe	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951FR-GP	France	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006

0951GB-GP	Great Britain	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951IE-GP	Ireland	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951JP-GP	Japan	Improved Native Chemical Ligation with Three or More Components	2003-502022	5/31/2002	4327589	6/19/2009
0951LU-GP	Luxembourg	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951MC-GP	Monaco	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951NL-GP	Netherlands	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951PCT-GP	PCT	Improved Native Chemical Ligation with Three or More Components	PCT/IB02/02949	5/31/2002		
0951SE-GP	Sweden	Improved Native Chemical Ligation with Three or More Components	2749204	5/31/2002	1392718	1/11/2006
0951US-UTL-GP	United States	Improved Native Chemical Ligation with Three or More Components	10/476447	5/31/2002	7662914	2/16/2010
0953JP-GP	Japan	Chemical Peptide Ligation of Three or More Peptide Fragments	2003-544070	11/14/2002	4399627	11/6/2009
0953US-PRO-GP	United States	Chemical Peptide Ligation with Three or More Components	60/353823	1/31/2002		
0953US-UTL-GP	United States	Chemical Peptide Ligation with Three or More Compounds	10/494928	11/14/2002	7884182	2/8/2011
0964AU-GP	Australia	Side-Chain Extended Ligation	2006257080	6/16/2006		
0964CA-GP	Canada	Side-Chain Extended Ligation	2612274	6/16/2006		
0964CH-GP	Switzerland	Side-Chain Extended Ligation	6754416.3	6/16/2006	1904515	12/8/2010
0964CN-GP	China P.R.	Side-Chain Extended Ligation	200680029597.6	6/16/2006		
0964DE-GP	Germany	Side-Chain Extended Ligation	6754416.3	6/16/2006	6.02006E+11	12/8/2010
0964EP-GP	Europe	Side-Chain Extended Ligation	6754416.3	6/16/2006	1904515	12/8/2010
0964ES-GP	Spain	Side-Chain Extended Ligation	6754416.3	6/16/2006	2355744	12/8/2010
0964FR-GP	France	Side-Chain Extended Ligation	6754416.3	6/16/2006	1904515	12/8/2010

0964GB-GP	Great Britain	Side-Chain Extended Ligation	6754416.3	6/16/2006	1904515	12/8/2010
0964IE-GP	Ireland	Side-Chain Extended Ligation	6754416.3	6/16/2006	1904515	12/8/2010
0964IL-GP	Israel	Side-Chain Extended Ligation	188154	6/16/2006		
0964IN-GP	India	Side-Chain Extended Ligation	9944/DELNP/2007	6/16/2006		
0964IT-GP	Italy	Side-Chain Extended Ligation	6754416.3	6/16/2006	1904515	12/8/2010
0964JP-GP	Japan	Side-Chain Extended Ligation	2008-516246	6/16/2006		
0964PCT-GP	PCT	Side-Chain Extended Ligation	PCT/EP2006/005815	6/16/2006		
0964US-PRO-GP	United States	Side-Chain Extended Ligation	60/691396	6/16/2005		
0964US-UTL	United States	Side-Chain Extended Ligation	11/917636	6/16/2006		
0965IN1-LL	India	Pharmaceutical Formulations and Methods for Making the Same	4505/DELNP/2009	12/11/2007		
0965US-PRO1	United States	Pharmaceutical Formulations and Methods for Making Same	60/874647	12/12/2006		
0965WO1	PCT	Pharmaceutical Formulations and Methods for Making the Same	PCT/US2007/025382	12/11/2007		
1001AU1	Australia	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	2007227202	3/21/2007		
1001CA1	Canada	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	2646598	3/21/2007		
1001CN1	China P.R.	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	200780012041.0	3/21/2007	ZL200780012041	4/4/2012
1001EP1	Europe	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	7753765.2	3/21/2007		
1001IN1	India	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	7603/DELNP/2008	3/21/2007		
1001JP1	Japan	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	2009-501566	3/21/2007		
1001US-CON1	United States	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	12/785396	3/21/2007		
1001US-PRO	United States	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	60/784795	3/21/2006		

1001US-UTL1	United States	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	12/293389	3/21/2007		
1001WO1	PCT	Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same	PCT/US2007/007163	3/21/2007		
1002EP1	Europe	Peptide-Peptidase Inhibitor Conjugates and Methods of Making and Using Same	8833915.5	9/26/2008		
1002IN1	India	Peptide-Peptidase Inhibitor Conjugates and Methods of Making and Using Same	2039/DELNP/2010	9/26/2008		
1002US-PRO1	United States	Peptide-Peptidase Inhibitor Conjugates and Methods of Making and Using Same	60/975776	9/27/2007		
1002US-UTL1	United States	Peptide-Peptidase Inhibitor Conjugates and Methods of Making and Using Same	12/680539	9/26/2008		
1002WO1	PCT	Peptide-Peptidase Inhibitor Conjugates and Methods of Making and Using Same	PCT/US2008/77955	9/26/2008		
1101MX1-LL	Mexico	Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases	MX/A/2008/012221	3/23/2007		
1101US-PRO	United States	Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases	60/785447	3/23/2006		
1101WO1	PCT	Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases	PCT/US2007/007376	3/23/2007		
1201AU1	Australia	Compositions and Methods for Treating Obesity and Related Metabolic Disorders	2006329836	12/15/2006		
1201EP1	Europe	Compositions and Methods for Treating Obesity and Related Metabolic Disorders	6845564.1	12/15/2006		
1201IN1	India	Compositions and Methods for Treating Obesity and Related Metabolic Disorders	5153/DELNP/2008	12/15/2006		
1201JP1	Japan	Compositions and Methods for Treating Obesity and Related Metabolic Disorders	2008-545850	12/15/2006		
1201US-PRO	United States	Compositions and Methods for Treating Obesity and Related Metabolic Disorders	60/751412	12/16/2005		
1201US-UTL1	United States	Compositions and Methods for Treating Obesity and Related Metabolic Disorders	12/097737	12/15/2006		
1201WO1	PCT	Compositions and Methods for Treating Obesity and Related	PCT/US2006/047953	12/15/2006		

		Metabolic Disorders				
1202EP1	Europe	Compositions and Methods for Treating Psychiatric Diseases and Disorders	8725173.2	2/4/2008		
1202US-PRO1	United States	Compositions and Methods for Treating Psychiatric Diseases and Disorders	60/899782	2/5/2007		
1202US-UTL1	United States	Neuromedin and FN-38 peptides for Treating Psychiatric Diseases	12/524903	2/4/2008		
1202WO1	PCT	Compositions and Methods for Treating Psychiatric Diseases and Disorders	PCT/US2008/001500	2/4/2008		
1317US-PRO2	United States	Engineered Polypeptides Having Enhanced Duration of Action	61/387402	9/28/2010		
1317US-PRO3	United States	Engineered Polypeptides Having enhanced Duration of Action	61/422091	12/10/2010		
1317WO1	PCT	Highly Soluble Leptins	PCT/US2011/053774	9/28/2011		
1317WO2	PCT	Engineered Polypeptides Having Enhanced Duration of Action	PCT/US2011/053786	9/28/2011		
1320US-PRO1	United States	Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	61/506001	7/8/2011		
1320US-PRO2	United States	Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	61/540422	9/28/2011		
1320WO	PCT	Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	To Be Determined	7/3/2012		
1321US-PRO1	United States	Leptin Antagonists Having Enhanced Duration of Action	61/616717	3/28/2012		
1801US-DIV1	United States	Mixing Tool	13/407518	4/25/2008		
1801US-PRO1	United States	Mixing Tool	60/914470	4/27/2007		
1801US-UTL1	United States	Mixing Tool	12/597352	4/25/2008	8147477	4/3/2012
1801WO1	PCT	Mixing Tool	PCT/US08/061653	4/25/2008		
1802US-PRO1	United States	Drug Delivery Device	60/914461	4/27/2007		
1802US-UTL1	United States	Drug Delivery Device	12/597468	10/23/2009		
1802WO1	PCT	Drug Delivery Device	PCT/US08/061666	4/25/2008		
1803EP1	Europe	Pen Injection Device and Method of Using Same	8781892.8	7/16/2008		

1803US-PRO1	United States	Semi-Automated Drug Resuspension and Delivery Device	60/951179	7/20/2007		
1803US-UTL1	United States	Pen Injection Device and Method of Using Same	12/669255	7/16/2008		
1803WO1	PCT	Pen Injection Device and Method of Using Same	PCT/US2008/070172	7/16/2008		
1804US-PRO1	United States	Formulation Delivery Device	61/105364	10/14/2008		
1804US-UTL	United States	Formulation Delivery Device	12/579028	10/14/2009		
1805US-PRO1	United States	Hypodermic Needle Assembly Having a Transition Hub for Enhancing Fluid Dynamics and Microsphere Injectability	61/335559	1/8/2010		
1805WO	PCT	Hypodermic Needle Assembly Having a Transition Hub for Enhancing Fluid Dynamics and Microsphere Injectability	PCT/US2011/020567	1/7/2011		
183/272CA	Canada	Use of Amylin Agonists in the Treatment of Diabetes Mellitus	575792	8/26/1988	1341060	7/25/2000
193/152AT	Austria	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152AU	Australia	Novel Amylin Agonist Peptides and Uses Therefor	30753/92	11/19/1992	673147	2/18/1997
193/152AU-D1	Australia	Novel Amylin Agonist Peptides and Uses Therefor	12456/97	11/19/1992	714439	4/20/2000
193/152BE	Belgium	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152CA	Canada	Novel Amylin Agonist Peptides and Uses Therefor	2100745	11/19/1992	2100745	7/31/2007
193/152CH	Switzerland	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152CZ	Czech Republic	Novel Amylin Agonist Peptides and Uses Therefor	PV1689-93	11/19/1992	288029	2/5/2001
193/152DE	Germany	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	P69232064.4-08	9/19/2001
193/152DK	Denmark	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152EP	Europe	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152ES	Spain	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	2161697	9/19/2001
193/152FI	Finland	Novel Amylin Agonist Peptides and Uses Therefor	933252	11/19/1992	118601	1/15/2008
193/152FR	France	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152GB	Great Britain	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152GR	Greece	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	3036794	9/19/2001

193/152HU	Hungary	Novel Amylin Agonist Peptides and Uses Therefor	P9302061	11/19/1992	222249	3/5/2003
193/152IE	Ireland	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152IT	Italy	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152JP	Japan	Novel Amylin Agonist Peptides and Uses Therefor	509441/1993	11/19/1992	2902115	3/19/1999
193/152JP-D3	Japan	Novel Amylin Agonist Peptides and Uses Therefor	2006-027334	2/3/2006	4018116	9/28/2007
193/152KR	Korea South	Novel Amylin Agonist Peptides and Uses Therefor	702152/1993	11/19/1992	303760	7/13/2001
193/152LU	Luxembourg	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152MC	Monaco	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152NL	Netherlands	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/152NO	Norway	Novel Amylin Agonist Peptides and Uses Therefor	1993 2603	11/19/1992	324405	10/8/2007
193/152PCT	PCT	Novel Amylin Agonist Peptides and Uses Therefor	PCT/US92/09842	11/19/1992		
193/152RU	Russia	Novel Amylin Agonist Peptides and Uses Therefor	93053497	11/19/1992	2130463	5/20/1999
193/152SE	Sweden	Novel Amylin Agonist Peptides and Uses Therefor	92924442.4	11/19/1992	567626	9/19/2001
193/153AU	Australia	Novel Amylin Antagonist Peptides and Uses Therefor	31431/93	11/19/1992	672589	1/29/1997
193/153US	United States	Novel Amylin Antagonist Peptides and Uses Therefor	07/794288	11/19/1991	5580953	12/3/1996
193/153WO	PCT	Novel Amylin Antagonist Peptides and Uses Therefor	PCT/US92/10011	11/19/1992		
199/054EP	Europe	Production of Peptide Amides	92917792.1	8/8/1992	598034	11/4/1998
199/054GB	Great Britain	Production of Peptide Amides	92917792.1	8/8/1992	598034	11/4/1998
199/054SE	Sweden	Production of Peptide Amides	92917792.1	8/8/1992	598034	11/4/1998
199/054US	United States	Production of Peptide Amides	07/927755	8/10/1992	5503969	4/2/1996
199/054WO	PCT	Production of Peptide Amides	PCT/US92/06604	8/8/1992		
201/115US	United States	Selective Amylin Antagonist Peptides and Uses Therefor	08/096172	7/21/1993	5625032	4/29/1997
201/115WO	PCT	Selective Amylin Antagonist Peptides and Uses Therefor	PCT/US94/08380	7/21/1994		
202/092EP	Europe	Antibody Assay for Amylin	93913922.6	5/17/1993	594843	11/3/2004

202/092NZ	New Zealand	Antibody Assay for Amylin	253449	5/17/1993	253449	4/19/1995
207/162US	United States	Methods and Compositions for Treatment of Diabetes Mellitus, Hypoglycemia and Other Conditions	08/259755	6/10/1994	5508260	4/16/1996
208/032US	United States	Method and Composition for Treatment of Insulin Requiring Mammals	08/259762	6/13/1994	5814600	9/29/1998
208/053US	United States	Methods and Compositions for Treatment of Diabetes Mellitus, Hypoglycemia and Other Conditions	08/260493	6/14/1994	5527771	6/18/1996
209/146AT	Austria	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146BE	Belgium	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146CA	Canada	Methods for Regulating Gastrointestinal Motility	2171207	9/7/1994	2171207	3/30/2010
209/146CH	Switzerland	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146DE	Germany	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	69426304.4	11/15/2000
209/146DK	Denmark	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146EP	Europe	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146ES	Spain	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	2154299	11/15/2000
209/146FR	France	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146GB	Great Britain	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146GR	Greece	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	3035387	11/15/2000
209/146IE	Ireland	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146IT	Italy	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146JP	Japan	Methods for Regulating Gastrointestinal Motility	508823/1995	9/7/1994	3821839	6/30/2006
209/146KR	Korea South	Methods for Regulating Gastrointestinal Motility	701160/1996	9/7/1994	10-391399	7/2/2003
209/146KR-D1	Korea South	Methods for Regulating Gastrointestinal Motility	10-2003-7005868	9/7/1994	10-429966	4/21/2004
209/146LU	Luxembourg	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146MC	Monaco	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000

209/146NL	Netherlands	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146PCT	PCT	Methods for Regulating Gastrointestinal Motility	PCT/US94/10225	9/7/1994		
209/146PT	Portugal	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146RU	Russia	Methods for Regulating Gastrointestinal Motility	96107891	9/7/1994	2177331	12/27/2001
209/146SE	Sweden	Methods for Regulating Gastrointestinal Motility	94927398.1	9/7/1994	717635	11/15/2000
209/146SG	Singapore	Methods for Regulating Gastrointestinal Motility	9607979.3	9/7/1994	98356	11/28/2003
209/146US	United States	Methods for Regulating Gastrointestinal Motility	08/302069	9/7/1994	6114304	9/5/2000
209/284US	United States	Treatment of Diabetes Mellitus	08/341342	11/17/1994	5641744	6/24/1997
2101AU1-LL	Australia	Sustained Release Formulations Using Non-Aqueous Carriers	2009289529	9/4/2009		
2101BR1-LL	Brazil	Sustained Release Formulations Using Non-Aqueous Carriers	PI0918904-1	9/4/2009		
2101CA1-LL	Canada	Sustained Release Formulations Using Non-Aqueous Carriers	2734525	9/4/2009		
2101CN1-LL	China P.R.	Sustained Release Formulations Using Non-Aqueous Carriers	200980134725.7	9/4/2009		
2101EA1-LL	Eurasia	Sustained Release Formulations Using Non-Aqueous Carriers	201170413	9/4/2009		
2101EP1-LL	Europe	Sustained Release Formulations Using Non-Aqueous Carriers	9812292.2	9/4/2009		
2101HK1-LL	Hong Kong	Sustained Release Formulations Using Non-Aqueous Carriers	11107414	9/4/2009		
2101IL1-LL	Israel	Sustained Release Formulations Using Non-Aqueous Carriers	211231	9/4/2009		
2101IN1-LL	India	Sustained Release Formulations Using Non-Aqueous Carriers	1498/DELNP/2011	9/4/2009		
2101JP1-LL	Japan	Sustained Release Formulations Using Non-Aqueous Carriers	2011-526233	9/4/2009		
2101KR1-LL	Korea South	Sustained Release Formulations Using Non-Aqueous Carriers	10-2011-7007223	9/4/2009		
2101MX1-LL	Mexico	Sustained Release Formulations Using Non-Aqueous Carriers	MX/A/2011/0023	3/3/2011		
2101NZ1-LL	New Zealand	Sustained Release Formulations Using Non-Aqueous Carriers	591208	9/4/2009		
2101SG1-LL	Singapore	Sustained Release Formulations Using Non-Aqueous Carriers	201101519-5	9/4/2009		
2101US-PRO1	United States	Formulations for the Sustained Release of Active Pharmaceutical Ingredients	61/094381	9/4/2008		

2101US-UTL-LL	United States	Sustained Release Formulations Using Non-Aqueous Carriers	13/060225	9/4/2009		
2101WO1	PCT	Sustained Release Formulations Using Non-Aqueous Carriers	PCT/US2009/056058	9/4/2009		
2102US-PRO1-LL	United States	Methods for Treating Diabetes with Extended Release Formulations of GLP-1 Receptor Agonists	61/601018	6/24/2011		
2102US-PRO2	United States	Methods for Treating Diabetes with Extended Release Formulations of GLP-1 Receptor Agonists	61/657595	6/8/2012		
2102WO1	PCT	Methods for Treating Diabetes with Extended Release Formulations of GLP-1 Receptor Agonists	PCT/US2012/43615	6/21/2012		
212/048US	United States	Amylin Activity Assays	08/422747	4/14/1995	6048514	4/11/2000
213/048US	United States	Methods for Regulating Gastrointestinal Motility	08/471675	6/5/1995	5795861	8/18/1998
213/080CL	Chile	Amylin Agonist Peptides and Uses Therefor	1873-2004	7/26/2004		
213/080US	United States	Amylin Agonist Peptides and Uses Therefor	08/447849	5/23/1995	5686411	11/11/1997
213/080US-PTE	United States	Amylin Agonist Peptides and Uses Therefor	08/447849	5/12/2005	5686411	10/4/2007
214/005US	United States	Appetite Regulating Compositions [Amylin]	08/477727	6/7/1995	5739106	4/14/1998
214/005WO	PCT	Appetite Regulating Compositions [Amylin]	PCT/US96/09937	6/6/1996		
214/072AT	Austria	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072AU	Australia	Treatment of Type II Diabetes Mellitus with Amylin Agonists	62685/96	6/7/1996	721489	10/19/2000
214/072BE	Belgium	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072CA	Canada	Treatment of Type II Diabetes Mellitus with Amylin Agonists	2196989	6/7/1996		
214/072CH	Switzerland	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072CZ	Czech Republic	Treatment of Type II Diabetes Mellitus with Amylin Agonists	PV337-97	6/7/1996	289043	8/23/2001
214/072DE	Germany	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	69625157.4	12/4/2002
214/072DK	Denmark	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072EP	Europe	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072ES	Spain	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	2187659	12/4/2002

214/072FI	Finland	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072FR	France	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072GB	Great Britain	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072GR	Greece	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	3043066	12/4/2002
214/072IE	Ireland	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072IN	India	A Process for Preparing a Pharmaceutical Composition Containing Amylin Agonist for Treatment of Type II Diabetes Mellitus	1053/CAL/96	6/7/1996	181672	7/30/1999
214/072IT	Italy	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072JP	Japan	Treatment of Type II Diabetes Mellitus with Amylin Agonists	502061/1997	6/7/1996	4009319	9/7/2007
214/072LU	Luxembourg	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072MC	Monaco	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072NL	Netherlands	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072PCT	PCT	Treatment of Type II Diabetes Mellitus with Amylin Agonists	PCT/US96/09875	6/7/1996		
214/072PH	Philippines	Treatment of Type II Diabetes Mellitus with Amylin Agonists	53368	6/7/1996	1-1996-53368	10/12/2001
214/072PT	Portugal	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072RU	Russia	Treatment of Type II Diabetes Mellitus with Amylin Agonists	97104029	6/7/1996	2166958	10/24/2000
214/072SE	Sweden	Treatment of Type II Diabetes Mellitus with Amylin Agonists	96921467.5	6/7/1996	772451	12/4/2002
214/072SG	Singapore	Treatment of Type II Diabetes Mellitus with Amylin Agonists	9701376-7	6/7/1996	39132	9/28/1998
214/072US	United States	Treatment of Type II Diabetes Mellitus with Amylin Agonists	08/483188	6/7/1995	6143718	11/7/2000
214/072US-CON1	United States	Treatment of Type II Diabetes Mellitus with Amylin Agonists	09/707370	11/6/2000	6417164	7/9/2002
219/232AU	Australia	Methods and Compositions for Treating Pain	77356/98	12/12/1997	727688	4/5/2001
219/232CA	Canada	Methods and Compositions for Treating Pain	2274967	12/12/1997	2274967	10/13/2009
219/232US	United States	Methods and Compositions for Treating Pain with Amylin or Agonists Thereof	08/767169	12/16/1996	5677279	10/14/1997

219/232WO	PCT	Methods and Compositions for Treating Pain	PCT/US97/23015	12/12/1997		
2201US-PRO1	United States	Formulations	61/495282	6/9/2011		
2202US-PRO1	United States	Gel Compositions	61/500042	6/22/2011		
2202WO	PCT	Gel Compositions	PCT/US2012/041519	6/8/2012		
221/063AT-LL	Austria	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	E417622	12/17/2008
221/063AU-D1-LL	Australia	Methods for Regulating Gastrointestinal Motility	91388/01	8/8/1997	782977	1/5/2006
221/063AUD2-LL	Australia	Methods for Regulating Gastrointestinal Motility	2005242228	8/8/1997	2005242228	10/9/2008
221/063AUD2SPC	Australia	Methods for Regulating Gastrointestinal Motility	2005242228	4/9/2009	2005242228	10/29/2009
221/063BE-LL	Belgium	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063CA-LL	Canada	Methods for Regulating Gastrointestinal Motility	2262647	8/8/1997	2262647	12/4/2007
221/063CH1-LL	Switzerland	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063CH-LL	Switzerland	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063DE1-LL	Germany	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	69740096.4	1/5/2011
221/063DE-LL	Germany	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	69739172.8-08	12/17/2008
221/063DK1-LL	Denmark	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063DK-LL	Denmark	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063EP-D1-LL	Europe	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063EP-LL	Europe	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063ES1-LL	Spain	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2359031	1/5/2011
221/063ES-LL	Spain	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	2319936	12/17/2008
221/063FI-LL	Finland	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063FR1-LL	France	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063FR-LL	France	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063GB1-LL	Great Britain	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011

221/063GB-LL	Great Britain	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063GR-LL	Greece	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	3068232	12/17/2008
221/063IE1-LL	Ireland	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063IE-LL	Ireland	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063IT1-LL	Italy	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063IT-LL	Italy	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063LU-LL	Luxembourg	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063MC-LL	Monaco	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063NL1-LL	Netherlands	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063NL-LL	Netherlands	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063PCT	PCT	Methods for Regulating Gastrointestinal Motility	PCT/US97/14199	8/8/1997		
221/063PT-LL	Portugal	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
221/063SE1-LL	Sweden	Pharmaceutical Composition Comprising an Exendin-4 Peptide	8016667.1	8/8/1997	2016950	1/5/2011
221/063SE-LL	Sweden	Methods for Regulating Gastrointestinal Motility	97938261.1	8/8/1997	966297	12/17/2008
222/239AU	Australia	Novel Mixed Amylin Activity Compounds	26612/99	2/5/1999	766653	2/5/2004
222/239CA	Canada	Novel Mixed Amylin Activity Compounds	2320962	2/5/1999	2320962	4/19/2011
222/239DE	Germany	Novel Mixed Amylin Activity Compounds	99906782	2/5/1999	69943039.9-08	12/15/2010
222/239EP	Europe	Novel Mixed Amylin Activity Compounds	99906782	2/5/1999	1053001	12/15/2010
222/239ES	Spain	Novel Mixed Amylin Activity Compounds	99906782	2/5/1999	2356595	12/15/2010
222/239FR	France	Novel Mixed Amylin Activity Compounds	99906782	2/5/1999	1053001	12/15/2010
222/239GB	Great Britain	Novel Mixed Amylin Activity Compounds	99906782	2/5/1999	1053001	12/15/2010
222/239IT	Italy	Novel Mixed Amylin Activity Compounds	99906782	2/5/1999	1053001	12/15/2010
222/239JP	Japan	Novel Mixed Amylin Activity Compounds	2000-531179	2/5/1999	4372345	9/11/2009
222/239PCT	PCT	Novel Mixed Amylin Activity Compounds	PCT/US99/02603	2/5/1999		

222/239US	United States	Novel Mixed Amylin Activity Compounds	60/074746	2/13/1998		
223/080US	United States	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	60/034905	1/7/1997		
223/207US	United States	Amylin Agonist Pharmaceutical Compositions Containing Insulin	60/035141	1/8/1997		
224/042US	United States	Method for Preventing Gastritis Using Amylin or Amylin Agonists	08/851965	5/6/1997	7101853	9/5/2006
224/264US	United States	Novel Uncoupling Protein and Methods of Use	60/043407	4/4/1997		
225/230US	United States	Novel Uncoupling Protein and Methods of Use	60/046154	5/8/1997		
226/067AU-D3-LL	Australia	Inotropic and Diuretic Effects of Exendin and GLP1	2006252240	2/5/1999	2006252240	6/4/2009
226/067AU-LL	Australia	Inotropic and Diuretic Effects of Exendin and GLP1	26596/99	2/5/1999	759058	7/17/2003
226/067CA-LL	Canada	Inotropic and Diuretic Effects of Exendin and GLP1	2320371	2/5/1999	2320371	1/17/2012
226/067DE-LL	Germany	Inotropic and Diuretic Effects of Exendin and GLP1	99906762.2	2/5/1999	69936446.9-08	7/4/2007
226/067EP-LL	Europe	Inotropic and Diuretic Effects of Exendin and GLP1	99906762.2	2/5/1999	1054594	7/4/2007
226/067ES-LL	Spain	Inotropic and Diuretic Effects of Exendin and GLP1	99906762.2	2/5/1999	2291017	7/4/2007
226/067FR-LL	France	Inotropic and Diuretic Effects of Exendin and GLP1	99906762.2	2/5/1999	1054594	7/4/2007
226/067GB-LL	Great Britain	Inotropic and Diuretic Effects of Exendin and GLP1	99906762.2	2/5/1999	1054594	7/4/2007
226/067IT-LL	Italy	Inotropic and Diuretic Effects of Exendin and GLP1	99906762.2	2/5/1999	1054594	7/4/2007
226/067JP-LL	Japan	Inotropic and Diuretic Effects of Exendin and GLP1	2000-531064	2/5/1999	4677095	2/4/2011
226/067US	United States	Inotropic and Diuretic Effects of Exendin and GLP1	60/075122	2/13/1998		
226/067WO	PCT	Inotropic and Diuretic Effects of Exendin and GLP1	PCT/US99/02554	2/5/1999		
226/104US	United States	Methods for Treating Obesity	08/870762	6/6/1997	7910548	3/22/2011
226/107PCT	PCT	Transgenic Mammals Lacking Expression of Amylin	PCT/US97/09887	6/6/1997		
226/137US	United States	Novel Exendin Agonist Compounds	60/055404	8/8/1997		
226/138AU	Australia	Novel Anti-Diabetic Peptides	53430/99	8/9/1999	766545	1/30/2004
226/138CA	Canada	Novel Anti-Diabetic Peptides	2337971	8/9/1999	2337971	4/26/2011

226/138DE	Germany	Novel Anti-Diabetic Peptides	99939073.5	8/9/1999	69935229.0-08	2/21/2007
226/138EP	Europe	Novel Anti-Diabetic Peptides	99939073.5	8/9/1999	1104438	2/21/2007
226/138ES	Spain	Novel Anti-Diabetic Peptides	99939073.5	8/9/1999	1104438	2/21/2007
226/138FR	France	Novel Anti-Diabetic Peptides	99939073.5	8/9/1999	1104438	2/21/2007
226/138GB	Great Britain	Novel Anti-Diabetic Peptides	99939073.5	8/9/1999	1104438	2/21/2007
226/138IT	Italy	Novel Anti-Diabetic Peptides	99939073.5	8/9/1999	1104438	2/21/2007
226/138JP	Japan	Novel Anti-Diabetic Peptides	2000-566301	8/9/1999		
226/138US	United States	Novel Anti-Diabetic Peptides	09/138056	8/21/1998	6087334	7/11/2000
226/138WO	PCT	Novel Anti-Diabetic Peptides	PCT/US99/17918	8/9/1999		
227/006CL	Chile	Novel Amylin Agonist Peptides and Uses Therefor	1874-2004	7/26/2004	47901	8/29/2011
227/006US	United States	Pramlintide Pro H-Amylin Salts and Compositions	08/892549	7/14/1997	5998367	12/7/1999
227/166US-LL	United States	Methods for Regulating Gastrointestinal Motility	08/908867	8/8/1997	6858576	2/22/2005
227/185US	United States	Novel Exendin Agonist Compounds	60/065442	11/14/1997		
230/219US	United States	Novel Exendin Agonist Compounds	60/066029	11/14/1997		
231/181AT-LL	Austria	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	E304864	9/21/2005
231/181AU-LL	Australia	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	6239498	1/7/1998	739020	1/17/2002
231/181BE-LL	Belgium	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181CA	Canada	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	2277112	1/7/1998	2277112	8/26/2008
231/181CH-LL	Switzerland	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181DE-LL	Germany	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	69831673.8-08	9/21/2005
231/181DK-LL	Denmark	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005

231/181EP-D1	Europe	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	5011978.3	1/7/1998		
231/181EP-LL	Europe	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181ES-LL	Spain	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	2247676	9/21/2005
231/181FI-LL	Finland	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181FR-LL	France	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181GB-LL	Great Britain	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181GR-LL	Greece	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	3055240	9/21/2005
231/181HK-LL	Hong Kong	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	104513	7/21/2000	1025252	11/25/2005
231/181IE-LL	Ireland	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181IT-LL	Italy	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181JP-LL	Japan	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	531147/1998	1/7/1998	4798814	8/12/2011
231/181LU-LL	Luxembourg	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181MC-LL	Monaco	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181NL-LL	Netherlands	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181PCT	PCT	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	PCT/US98/00449	1/7/1998		
231/181PT-LL	Portugal	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005
231/181SE-LL	Sweden	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	98904545.5	1/7/1998	996459	9/21/2005

		Intake				
231/181US-LL	United States	Use of Exendins and Agonists Thereof for the Reduction of Food Intake	09/003869	1/7/1998	6956026	10/18/2005
231/182AU	Australia	Formulations for Amylin Agonist Peptides	59094/98	1/9/1998	760609	8/28/2003
231/182CA	Canada	Formulations for Amylin Agonist Peptides	2365742	1/9/1998		
231/182CH	Switzerland	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182CL	Chile	Formulations for Amylin Agonist Peptides	1875-2004	7/26/2004		
231/182DE	Germany	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	69840106.9-08	10/8/2008
231/182DK	Denmark	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182EP	Europe	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182ES	Spain	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	2316161	10/8/2008
231/182FR	France	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182GB	Great Britain	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182IT	Italy	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182JP	Japan	Formulations for Amylin Agonist Peptides	534939/1999	1/9/1998	4353544	8/7/2009
231/182JP-D1	Japan	Formulations for Amylin Agonist Peptides	2009-058075	1/9/1998		
231/182NL	Netherlands	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182PCT	PCT	Formulations for Amylin Agonist Peptides	PCT/US98/00288	1/9/1998		
231/182SE	Sweden	Formulations for Amylin Agonist Peptides	98902423.7	1/9/1998	1044015	10/8/2008
231/182US	United States	Formulations for Amylin Agonist Peptides	09/005262	1/9/1998	6410511	6/25/2002
234/169CA	Canada	Method for Preventing Gastritis Using Amylin or Amylin Agonists	2289548	5/6/1998		
234/169DE	Germany	Method for Preventing Gastritis Using Amylin or Amylin Agonists	98920218.9	5/6/1998	69839423.2	4/30/2008
234/169EP	Europe	Method for Preventing Gastritis Using Amylin or Amylin Agonists	98920218.9	5/6/1998	981360	4/30/2008
234/169ES	Spain	Method for Preventing Gastritis Using Amylin or Amylin Agonists	98920218.9	5/6/1998	2302353	4/30/2008

234/169FR	France	Method for Preventing Gastritis Using Amylin or Amylin Agonists	98920218.9	5/6/1998	981360	4/30/2008
234/169GB	Great Britain	Method for Preventing Gastritis Using Amylin or Amylin Agonists	98920218.9	5/6/1998	981360	4/30/2008
234/169IT	Italy	Method for Preventing Gastritis Using Amylin or Amylin Agonists	98920218.9	5/6/1998	981360	4/30/2008
234/169JP	Japan	Method for Preventing Gastritis Using Amylin or Amylin Agonists	548352/1998	5/6/1998		
234/169PCT	PCT	Method for Preventing Gastritis Using Amylin or Amylin Agonists	PCT/US98/09089	5/6/1998		
235/013CZ	Czech Republic	Methods for Treating Obesity	PV4360-99	6/5/1998	294983	2/28/2005
235/013HU	Hungary	Methods for Treating Obesity	P0004271	6/5/1998		
235/013MX	Mexico	Methods for Treating Obesity	PA/A/1999/011320	6/5/1998	231005	10/3/2005
235/013NO	Norway	Methods for Treating Obesity	19995996	6/5/1998	324818	12/10/2007
235/013NZ	New Zealand	Methods for Treating Obesity	501451	6/5/1998	501451	2/5/2002
235/013PCT	PCT	Methods for Treating Obesity	PCT/US98/11753	6/5/1998		
235/013PL	Poland	Methods for Treating Obesity	P-338082	6/5/1998	193236B	6/23/2006
235/013RU	Russia	Methods for Treating Obesity	2000100346	6/5/1998	2207871	7/10/2003
235/013RU-D1	Russia	Methods for Treating Obesity	2002130192	6/5/1998	2314121	1/10/2008
235/013US-CON1	United States	Methods for Treating Obesity	13/445803	4/12/2012		
235/108US	United States	Uncoupling Protein 4 (UCP-4) and Methods of Use	60/092737	7/14/1998		
235/108US-UTL	United States	Uncoupling Protein 4 (UCP-4) and Methods of Use	09/743847	7/13/1999	6602694	8/5/2003
236/097AT	Austria	Novel Exendin Agonist Compounds	98939260	8/6/1998	E379458	11/28/2007
236/097AU	Australia	Novel Exendin Agonist Compounds	87729/98	8/6/1998	749914	10/24/2002
236/097BE	Belgium	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097CA	Canada	Novel Exendin Agonist Compounds	2299425	8/6/1998		
236/097CH	Switzerland	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097CY	Cyprus	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097DE	Germany	Novel Exendin Agonist Compounds	98939260	8/6/1998	69838791.0-08	11/28/2007

236/097DK	Denmark	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097EP	Europe	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097ES	Spain	Novel Exendin Agonist Compounds	98939260	8/6/1998	2293688T5	11/28/2007
236/097FI	Finland	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097FR	France	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097GB	Great Britain	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097GR	Greece	Novel Exendin Agonist Compounds	98939260	8/6/1998	3063985	11/28/2007
236/097IE	Ireland	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097IT	Italy	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097LU	Luxembourg	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097MC	Monaco	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097MX	Mexico	Novel Exendin Agonist Compounds	2000/001419	8/6/1998	258903	7/18/2008
236/097NL	Netherlands	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097NZ	New Zealand	Novel Exendin Agonist Compounds	502592	8/6/1998	502592	7/8/2002
236/097PT	Portugal	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097SE	Sweden	Novel Exendin Agonist Compounds	98939260	8/6/1998	1019077	11/28/2007
236/097US-DIV1	United States	Novel Exendin Agonist Compounds	11/511738	8/6/1998	7858740	12/28/2010
236/097US-DIV2	United States	Novel Exendin Agonist Compounds	12/959176	8/6/1998		
236/097US-UTL	United States	Novel Exendin Agonist Compounds	10/181102	8/6/1998	7157555	1/2/2007
236/097WO	PCT	Novel Exendin Agonist Compounds	PCT/US98/16387	8/6/1998		
236/104US	United States	Differentially Expressed Genes in the Adipocytes of Obese Mice	60/141515	6/22/1999		
238/086AU	Australia	Novel Exendin Agonist Compounds	14046/99	11/13/1998	757748	6/19/2003
238/086AU-D1	Australia	Novel Exendin Agonist Compounds	2003200129	11/13/1998	2003200129	10/5/2006
238/086AU-D2	Australia	Novel Exendin Agonist Compounds	2006225304	11/13/1998	2006225304	3/19/2009

238/086BE	Belgium	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086BR	Brazil	Novel Exendin Agonist Compounds	PI9815670-5	11/13/1998		
238/086CA	Canada	Novel Exendin Agonist Compounds	2310097	11/13/1998		
238/086CH	Switzerland	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086DE	Germany	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	69838916.6-08	12/26/2007
238/086EP	Europe	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086ES	Spain	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	2294822	12/26/2007
238/086FR	France	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086GB	Great Britain	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086HK	Hong Kong	Novel Exendin Agonist Compounds	1102942.4	4/25/2001	HK 1033465	5/9/2008
238/086IE	Ireland	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086IT	Italy	Novel Exendin Agonist Compounds	98957897.6	11/13/1998	1066314	12/26/2007
238/086MX	Mexico	Novel Exendin Agonist Compounds	PA/A/2000/004670	11/13/1998	PA/a/2000/0046	6/6/2008
238/086NZ	New Zealand	Novel Exendin Agonist Compounds	504258	11/13/1998	504258	3/31/2003
238/086SG	Singapore	Novel Exendin Agonist Compounds	200002431-5	11/13/1998	73021	1/31/2008
238/086US	United States	Novel Exendin Agonist Compounds	09/554533	11/13/1998	7223725	5/29/2007
238/086US-DIV1	United States	Exendin Agonist Compounds	11/807031	11/13/1998	7696161	4/13/2010
238/086WO	PCT	Novel Exendin Agonist Compounds	PCT/US96/24210	11/13/1998		
238/087AT	Austria	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	E383867	1/16/2008
238/087AU	Australia	Novel Exendin Agonist Compounds	14588/99	11/13/1998	756836	5/8/2003
238/087AU-D1	Australia	Novel Exendin Agonist Compounds	2003203955	11/13/1998	2003203955	10/12/2006
238/087AU-D2	Australia	Novel Exendin Agonist Compounds	2006225176	11/13/1998	2006225176	4/23/2009
238/087BE	Belgium	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087CA	Canada	Novel Exendin Agonist Compounds	2309356	11/13/1998	2309356	9/21/2010

238/087CH	Switzerland	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087CY	Cyprus	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087DE	Germany	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	69839021.0-08	1/16/2008
238/087DK	Denmark	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087EP	Europe	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087ES	Spain	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	2297902	1/16/2008
238/087FI	Finland	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087FR	France	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087GB	Great Britain	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087GR	Greece	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	3064557	1/16/2008
238/087HK	Hong Kong	Novel Exendin Agonist Compounds	1101595.6	3/17/2008	HK1031120	5/9/2008
238/087IE	Ireland	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087IT	Italy	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087LU	Luxembourg	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087MC	Monaco	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087MX	Mexico	Novel Exendin Agonist Compounds	2000/004671	11/13/1998	253623	1/21/2008
238/087NL	Netherlands	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087NZ	New Zealand	Novel Exendin Agonist Compounds	504256	11/13/1998	504256	5/12/2003
238/087PT	Portugal	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087SE	Sweden	Novel Exendin Agonist Compounds	98958573.2	11/13/1998	1032587	1/16/2008
238/087SG	Singapore	Novel Exendin Agonist Compounds	200002437-2	11/13/1998	73024	6/4/2002
238/087US	United States	Novel Exendin Agonist Compounds	09/554531	11/13/1998	7220721	5/22/2007
238/087WO	PCT	Novel Exendin Agonist Compounds	PCT/US98/24273	11/13/1998		
239/207US	United States	Novel Exendin Agonist Formulations and Methods of	60/116380	1/14/1999		

		Administration Thereof				
242/040US	United States	Modified Exendins and Exendin Agonists	60/132018	4/30/1999		
242/041US	United States	Use of Membranes, Cells and Tissue from the Area Postrema to Identify Therapeutic Compounds	60/143830	7/13/1999		
242/168US	United States	Methods for Glucagon Suppression	60/132017	4/30/1999		
243/131AT-LL	Austria	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	E367169	7/18/2007
243/131AU-D1	Australia	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	2005200608	5/23/2000	2005200608	5/22/2008
243/131AU-LL	Australia	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	52846/00	5/23/2000	778002	3/3/2005
243/131BE-LL	Belgium	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131CA-LL	Canada	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	2373266	5/23/2000	2373266	9/14/2010
243/131CH-LL	Switzerland	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131CY-LL	Cyprus	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131DE-LL	Germany	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	60035584.5-08	7/18/2007
243/131DK-LL	Denmark	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131EP-LL	Europe	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131ES-LL	Spain	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	2290039	7/18/2007
243/131FI-LL	Finland	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131FR-LL	France	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131GB-LL	Great Britain	Use of Exendins and Agonists Thereof for the Treatment of	937710.2	5/23/2000	1181043	7/18/2007

		Gestational Diabetes Mellitus				
243/131GR-LL	Greece	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	3063185	7/18/2007
243/131HK-LL	Hong Kong	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	2105767.8	8/7/2002	HK1044280	10/26/2007
243/131IE-LL	Ireland	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131IT-LL	Italy	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131LU-LL	Luxembourg	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131MC-LL	Monaco	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131NL-LL	Netherlands	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131PCT	PCT	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	PCT/US00/14231	5/23/2000		
243/131PT-LL	Portugal	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131SE-LL	Sweden	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	937710.2	5/23/2000	1181043	7/18/2007
243/131US-LL	United States	Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus	09/323867	6/1/1999	6506724	1/14/2003
246/091US	United States	High Affinity Exendin Receptors	60/166899	11/22/1999		
248/182US	United States	Novel Amylin Agonist Peptides and Uses Therefor	09/454533	12/6/1999	6610824	8/26/2003
248/182US-CON	United States	Amylin Agonist Peptides and Uses Therefor	10/649138	8/26/2003	7271238	9/18/2007
249/124AT-LL	Austria	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	E275967	9/15/2004
249/124AU-LL	Australia	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	26380/01	1/9/2001	784488	4/13/2006
249/124BE-LL	Belgium	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004

249/124CH-LL	Switzerland	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124CY-LL	Cyprus	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124DE-LL	Germany	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	60105547.0-08	9/15/2004
249/124DK-LL	Denmark	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124EP-LL	Europe	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124ES-LL	Spain	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	2227115	9/15/2004
249/124FI-LL	Finland	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124FR-LL	France	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124GB-LL	Great Britain	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124GR-LL	Greece	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	3051303	9/15/2004
249/124HK-LL	Hong Kong	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	3102440.9	4/4/2003	HK 1050477A	5/6/2005
249/124IE-LL	Ireland	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124IT-LL	Italy	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124LU-LL	Luxembourg	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124MC-LL	Monaco	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124NL-LL	Netherlands	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124PCT	PCT	Use of Exendins and Agonists Thereof for Modulation of	PCT/US01/00719	1/9/2001		

		Triglyceride Levels and Treatment of Dyslipidemia				
249/124PT-LL	Portugal	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124SE-LL	Sweden	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124TR-LL	Turkey	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	1900978.6	1/9/2001	1246638	9/15/2004
249/124US	United States	Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia	60/175365	1/10/2000		
249/146AT-LLN	Austria	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146AU-D1	Australia	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2005200206	1/14/2000	2005200206	5/31/2007
249/146AU-LL	Australia	Novel Exendin Agonist Formulations and Methods of Administration Thereof	35819/00	1/14/2000	777564	2/10/2005
249/146BE-LL	Belgium	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146BR-LL	Brazil	Novel Exendin Agonist Formulations and Methods of Administration Thereof	PI0007820-4	1/14/2000		
249/146CA-LL	Canada	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2356706	1/14/2000		
249/146CH-LL	Switzerland	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146CN-LL	China P.R.	Novel Exendin Agonist Formulations and Methods of Administration Thereof	804847.9	1/14/2000	ZL00804847.9	12/26/2007
249/146CY-LL	Cyprus	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146DE-LL	Germany	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	60021166.5-08	7/6/2005
249/146DK-LL	Denmark	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146EP-LL	Europe	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005

249/146ES-LL	Spain	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	2244416	7/6/2005
249/146FI-LL	Finland	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146FR-LL	France	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146GB-LL	Great Britain	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146GR-LL	Greece	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	3054635	7/6/2005
249/146HK-LL	Hong Kong	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2102346.5	3/27/2002	1040635B	9/2/2005
249/146IE-LL	Ireland	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146IN-LL	India	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2001/00729/CAL	1/14/2000		
249/146IT-LL	Italy	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146JP-LL	Japan	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2000-593167	1/14/2000	4426727	12/18/2009
249/146KR-LL	Korea South	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2001/7008904	1/14/2000	675711	1/23/2007
249/146LU-LL	Luxembourg	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146MC-LL	Monaco	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146NL-LL	Netherlands	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146NO-LL	Norway	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2001 3468	1/14/2000	331382	12/12/2011
249/146NZ-LL	New Zealand	Novel Exendin Agonist Formulations and Methods of Administration Thereof	512663	1/14/2000	512663	9/9/2004
249/146PCT	PCT	Novel Exendin Agonist Formulations and Methods of Administration Thereof	PCT/US00/00902	1/14/2000		

		Administration Thereof				
249/146PT-LL	Portugal	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146RU-LL	Russia	Novel Exendin Agonist Formulations and Methods of Administration Thereof	2001122722	1/14/2000	2242244	6/22/2004
249/146SE-LL	Sweden	Novel Exendin Agonist Formulations and Methods of Administration Thereof	914425.4	1/14/2000	1140145	7/6/2005
249/146SG-LL	Singapore	Novel Exendin Agonist Formulations and Methods of Administration Thereof	200103802-5	1/14/2000	81737	2/27/2004
249/146US-LL	United States	Novel Exendin Agonist Formulations and Methods of Administration Thereof	09/889330	1/14/2000	6902744	6/7/2005
249/167AT-LL	Austria	Methods for Glucagon Suppression	902415.9	1/14/2000	E347901	12/13/2006
249/167AU-D1	Australia	Methods for Glucagon Suppression	2004202293	1/14/2000	2004202293	1/4/2008
249/167AU-LL	Australia	Methods for Glucagon Suppression	24136/00	1/14/2000	770712	6/10/2004
249/167BE-LL	Belgium	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167BR-LL	Brazil	Methods for Glucagon Suppression	PI0007823-9	1/14/2000		
249/167CA-LL	Canada	Methods for Glucagon Suppression	2356331	1/14/2000	2356331	10/13/2009
249/167CH-LL	Switzerland	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167-CIP	United States	Exendin Analog Formulations	11/272488	1/14/2000	7399489	7/15/2008
249/167CN-LL	China P.R.	Methods for Glucagon Suppression	805017.1	1/14/2000	ZL00805017.1	10/15/2008
249/167-CON	United States	Methods for Glucagon Suppression Using Modified Exendins	11/083730	1/14/2000	7153825	12/26/2006
249/167-CON2	United States	Methods for Glucagon Suppression Using Modified Exendins	11/584114	1/14/2000	7407932	8/5/2008
249/167-CON3	United States	Exendins and Exendin Analogs to Treat Hyperglucagonemia	12/100880	1/14/2000		
249/167-CON4-LL	United States	Lyophilized Formulations of Exendins and Exendin Agonist Analogs	12/389509	1/14/2000	7906146	3/15/2011
249/167-CON5-LL	United States	Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs	13/045334	3/10/2011		
249/167CY-LL	Cyprus	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006

249/167DE1	Germany	Methods for Glucagon Suppression	6002683.8	1/14/2000	60044041.9-08	3/17/2010
249/167DE-LL	Germany	Methods for Glucagon Suppression	902415.9	1/14/2000	60032331.5-08	12/13/2006
249/167DK-LL	Denmark	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167EP-D1	Europe	Methods for Glucagon Suppression	6002683.8	1/14/2000	1658856	3/17/2010
249/167EP-LL	Europe	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167ES1	Spain	Methods for Glucagon Suppression	6002683.8	1/14/2000	2343072	3/17/2010
249/167ES-LL	Spain	Methods for Glucagon Suppression	902415.9	1/14/2000	2278589	12/13/2006
249/167FI-LL	Finland	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167FR1	France	Methods for Glucagon Suppression	6002683.8	1/14/2000	1658856	3/17/2010
249/167FR-LL	France	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167GB1	Great Britain	Methods for Glucagon Suppression	6002683.8	1/14/2000	1658856	3/17/2010
249/167GB-LL	Great Britain	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167GR-LL	Greece	Methods for Glucagon Suppression	902415.9	1/14/2000	3060878	12/13/2006
249/167IE-LL	Ireland	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167IT1	Italy	Methods for Glucagon Suppression	6002683.8	1/14/2000	1658856	3/17/2010
249/167IT-LL	Italy	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167LU-LL	Luxembourg	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167MC-LL	Monaco	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167NL-LL	Netherlands	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167NO-LL	Norway	Methods for Glucagon Suppression	20013469	1/14/2000	328077	11/23/2009
249/167NZ-LL	New Zealand	Methods for Glucagon Suppression	512657	1/14/2000	512657	5/10/2004
249/167PCT	PCT	Methods for Glucagon Suppression	PCT/US00/00942	1/14/2000		
249/167PT-LL	Portugal	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167RU-LL	Russia	Methods for Glucagon Suppression	2001122716	1/14/2000	2247575	3/1/2005

249/167SE-LL	Sweden	Methods for Glucagon Suppression	902415.9	1/14/2000	1143989	12/13/2006
249/167SG-LL	Singapore	Methods for Glucagon Suppression	200103800-9	1/14/2000	81736	9/30/2003
249/167-UTL-LL	United States	Methods for Glucagon Suppression	09/889331	1/14/2000	6872700	3/29/2005
253/204AU	Australia	Modified Exendins and Exendin Agonists	46863/00	4/28/2000	775063	10/28/2004
253/204AU-D1	Australia	Modified Exendins and Exendin Agonists	2004220727	4/28/2000	2004220727	1/24/2008
253/204BR	Brazil	Modified Exendins and Exendin Agonists	P10010705-0	4/28/2000		
253/204CA	Canada	Modified Exendins and Exendin Agonists	2372214	4/28/2000		
253/204EP	Europe	Modified Exendins and Exendin Agonists	928685.7	4/28/2000		
253/204EP-D1	Europe	Modified Exendins and Exendin Agonists	10011852	4/28/2000		
253/204IN	India	Modified Exendins and Exendin Agonists	2001/00992/DEL	4/28/2000	217666	4/10/2008
253/204IN-D1	India	A Polymer-modified Exendin or Agonist Analog of an Exendin	3723/DELNP/2005	4/28/2000	243868	11/10/2010
253/204NZ	New Zealand	Modified Exendins and Exendin Agonists	514916	4/28/2000	514916	10/7/2004
253/204PCT	PCT	Modified Exendins and Exendin Agonists	PCT/US00/11814	4/28/2000		
253/204SG	Singapore	Modified Exendins and Exendin Agonists	200106448-2	4/28/2000	84325	1/30/2004
253/204US	United States	Modified Exendins and Exendin Agonists	09/561226	4/28/2000	6924264	8/2/2005
253/204US-CON	United States	Modified Exendins and Exendin Agonists	11/174089	6/30/2005	8057822	11/15/2011
253/204US-CON2	United States	Methods of Treating Diabetes with Albumin-Conjugated Exendin Peptides	12/046036	3/11/2008	7683030	3/23/2010
253/204US-CON3	United States	Exendins and Exendin Agonists Modified with Albumin	12/101689	4/11/2008	7608692	10/27/2009
253/204US-CON4	United States	Exendins and Exendin Agonists Modified with Polyamino Acids	12/101818	4/11/2008	7691963	4/6/2010
253/204US-CON5	United States	Modified Exendins and Exendin Agonists (to target Lixisenatide)	13/296120	11/14/2011		
254/057US	United States	Methods for Regulating Gastrointestinal Motility	09/576062	5/22/2000	6608029	8/19/2003
255/292PCT	PCT	Polynucleotides Encoding Proexendin and Methods and Uses Thereof	PCT/CA98/0071	2/4/1998		
255/292US-PRO	United States	Polynucleotide Encoding Proexendin and Methods and Uses	60/037412	2/5/1997		

		Thereof				
255/292-JTL-LL	United States	Polynucleotides Encoding Proexendin, and Methods and Uses Thereof	09/019172	2/5/1998	6723530	4/20/2004
256/152-CON1-LL	United States	Methods of Treatment Using Exendin Peptides or GLP-1 Peptides	12/247141	2/5/1999	7928065	4/19/2011
256/152-CON2-LL	United States	Methods of Treatment Using Exendin Peptides or GLP-1 Peptides	13/080051	2/5/1999		
256/152-DIV	United States	Inotropic and Diuretic Effects of GLP-1 and GLP-1 Agonists	10/656093	2/5/1999	7442680	10/28/2008
256/152-UTL-LL	United States	Inotropic and Diuretic Effects of Exendin and GLP1	09/622105	2/5/1999	6703359	3/9/2004
256/153US	United States	Novel Mixed Amylin Activity Compounds	09/622104	2/5/1999	6936584	8/30/2005